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 Resumo 
A farmacoeconomia é uma disciplina que avalia o uso de medicamentos em termos de 
recursos na maximização da saúde da população. Dado que os recursos para os cuidados de 
saúde são finitos, a avaliação económica envolve a estimativa do custo de oportunidade, i.e., 
os benefícios marginais perdidos como resultado do deslocamento de tratamentos ou serviços 
existentes para financiar novos medicamentos. 
A farmacocinética é a ciência que visa o estudo do movimento de fármacos no organismo, o 
que inclui a absorção, distribuição, metabolismo e eliminação destes e seus metabolitos. Com 
o advento da química analítica e métodos de quantificação sofisticados, bem como de um 
aumento do poder de computação, a farmacocinética como ciência tem tido um 
desenvolvimento exponencial. Uma das áreas da farmacocinética que se tem desenvolvido 
mais é a farmacocinética populacional: apesar da farmacocinética de um fármaco poder ser 
estudada individualmente em cada indivíduo, a abordagem populacional é benéfica para o 
estudo de grupos de pacientes que são difíceis de investigar, como a população de bebés 
prematuros, pacientes com insuficiência hepática ou renal. 
Na farmacocinética populacional, cada indivíduo é avaliado simultaneamente com o modelo 
de efeitos mistos não-lineares (parametrização). Não linear significa que a variável 
dependente dessa concentração está relacionada não linearmente à associação de variáveis 
independentes e parâmetros do modelo. Efeitos fixos refere-se aos parâmetros que não se 
alteram em indivíduos, enquanto o efeito aleatório se refere àqueles parâmetros que se alteram 
através dos indivíduos. 
O principal objetivo das estimativas de modelação farmacocinética populacional é o de 
procurar os parâmetros de farmacocinética populacional e fonte de variabilidade. Os objetivos 
restantes consistem em concentrações observadas da dose administrada pela deteção das 
covariáveis preditivas na população avaliada. Em farmacocinética populacional, os indivíduos 
poderão apenas fornecer dados de concentração plasmática escassos.  
As cinco principais partes fundamentais para a construção de um modelo farmacocinético 
populacional incluem: dados, modelo estrutural, modelo estatístico, modelo de covariáveis e 
software de modelação. Os modelos estruturais definem o perfil de concentração plasmática 
ao longo do tempo nos indivíduos. Os modelos estatísticos descrevem a variabilidade 
aleatória na população que não é explicável (como a variabilidade entre as ocasiões), entre a 
variabilidade do indivíduo ou a variabilidade residual. Os modelos de covariável demonstram 
a variabilidade estimada pelas características da população, como covariáveis. O software de 
modelação, como o software de modelação de efeitos mistos não linear, permite a combinação 
de dados e modelos e aplica o método de estimativa para avaliar parâmetros para os modelos 
estatísticos, estruturais e de covariáveis que definem os dados. 
Na modelação farmacocinética populacional, o software possui um algoritmo de minimização 
do valor da função objetivo, praticando a estimativa de máxima verossimilhança. No 
momento da adaptação dos dados populacionais, a concentração estimada para cada indivíduo 
é influenciada pela variância dos parâmetros populacionais e de cada parâmetro individual, e 
 pela variação em cada valor das concentrações previstas e observadas. A avaliação da 
probabilidade marginal depende dos parâmetros de efeito aleatório (η) e efeito fixo da 
população. Não há existência de solução analítica para verossimilhança marginal. Enquanto 
buscava a máxima verossimilhança, inúmeras abordagens foram aplicadas para a aproximação 
da verossimilhança marginal. O FOCE e o LAPLACE são as abordagens mais antigas que 
estimam a verdadeira verossimilhança com uma função adicional simplificada. 
O trabalho de dissertação no âmbito do Mestrado em Ciências Biofarmacêuticas teve por 
objetivo o estabelecimento de ferramentas baseadas em simulação de dados com base em 
modelos farmacocinéticos populacionais para uma posterior análise farmacoeconómica. Neste 
trabalho utilizou-se a informação disponível para a combinação fixa de Glecaprevir e 
Pibrentasvir (Mavyret®), medicamento usado no tratamento do vírus da hepatite C crónica. 
As simulações foram realizadas utilizando o software R e seu pacote Shiny. O R é uma 
linguagem para análise de dados de computação estatística e gráfica. 
A população simulada no modelo foi agrupada de acordo com as covariáveis similares, sendo 
simulados 1000 indivíduos por cenário. O relatório de submissão da FDA do Mavyret® foi 
usado como referência na modelação farmacocinética populacional. Neste relatório encontra-
se descrito o modelo farmacocinético populacional desenvolvido, com base nos estudos 
clínicos realizados para o medicamento. No modelo descrito, foram identificadas diferentes 
covariáveis. O modelo descrito foi então implementado no software R e o impacto das 
covariáveis foi estudado com a aplicação Shiny. A população observada foi categorizada em 
diferentes grupos, tais como doentes tratados com Glecaprevir / Pibrentasvir com 
compromisso renal e doentes com compromisso renal e cirrose. Foram criados modelos 
individuais para cada um dos grupos e a comparação entre cada grupo e seus perfis de 
concentração-tempo foi realizada pelo uso do navegador R e Shiny, onde a atualização nos 
resultados pode ser vista automaticamente com a alteração em qualquer da covariável ou da 
variável. 
Para os diferentes modelos finais incorporados no software e para a população simulada, 
foram calculados os parâmetros farmacocinéticos AUC e Cmax para posterior análise 
estatística descritiva. 
Apesar da implementação dos modelos farmacocinéticos populacionais ter sido realizada em 
R e Shiny, e os dados terem sido simulados para os diferentes cenários populacionais, a 
aplicação de metodologias farmacoeconómicas não foram realizadas. 
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 Abstract  
Pharmacoeconomics is the discipline concerned with optimal allocation of resources to 
maximize population health from the use of medicines. Given that resources for health care 
are finite, economic evaluation involves estimation of the opportunity cost, that is, the 
marginal benefits forgone as a result of displacing existing treatments or services to fund new 
medicines. 
The purpose of this study is to use tools in pharmacoeconomic analysis for the examination of 
the positive and adverse impact of the fixed dose combination of Glecaprevir and Pibrentasvir 
(Mavyret
®
), used to treat chronic hepatitis C virus. In order to examine the effects in 
pharmacoeconomics analysis, a population pharmacokinetic model was developed using R 
software and its package Shiny, where R is a language for data analysis of statistical 
computing and graphics. 
The population simulated in the model was grouped according to the similar covariates with 
the number (n) of 1000. FDA submission report for Mavyret
®
 was used as reference regarding 
population pharmacokinetics modelling, developed based on the clinical studies performed 
for the drug product. In the described model, different covariates were identified. The 
described model was implemented in the R software and the impact of covariates wwas 
studied with Shiny application. The population observed was categorized in different groups 
such as patients treated with Glecaprevir/Pibrentasvir having renal impairment and patients 
with renal impairment and Cirrhosis. Individual models were created for each of the groups 
and the comparison between each group and their concentration-time profiles was observed 
that was made easier by the use of R and Shiny web browser where the update in results can 
be seen spontaneously with the change in any of the covariate or the variable. 
Different final models were produced and for the simulated population, the pharmacokinetic 
parameters AUC and Cmax were calculated for descriptive statistical analysis.  
Despite the implementation of population pharmacokinetics models has been accomplished in 
R and Shiny, and data has been simulated for different population scenarios, 
pharmacoeconomic modelling and application of pharmacoeconomic methodologies was not 
practised.  
Keywords 
Pharmacoeconomics, Pharmacokinetics, Population Pharmacokinetics, R Modelling, Shiny 
Application, Pharmacokinetic Statistics. 
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I. Introduction 
The macroeconomic factors are progressively affecting the budgets of healthcare. The 
limitations of these budgets can help in the measures of cost suppression in health care area. 
In health economics and outcome research, pharmacotherapy is also extensively involved. 
The relationship of pharmacoeconomic and pharmacokinetic has a significant role in the 
efficiency of pharmaceutical use. An appropriate pharmacokinetics is the basis of producing 
the cost-effective drugs aimed by the research and development investments. An appropriate 
monitoring of drug can aid in the adequate use of drugs with the cost-effective results. Thus, 
biopharmaceutics and pharmacokinetics assist in providing prospects for the proper use of 
novel or existing drugs and for balancing of adequate market share.  
Hence, pharmacokinetics can provide substantial economic benefits that are the normal 
outcome of their design as constrained drug input and prevention of high plasma 
concentrations resulting in toxic effect can be controlled by the diagnosis and treatment of 
adverse effects. The rational monitoring and improvements can eradicate the requirement of 
expensive re-examination of the drugs.  
1. Population Pharmacokinetics 
Pharmacokinetics is the science related to drug movement in the body that includes the 
absorption, distribution, metabolism and elimination of drugs and its metabolites [1]. It has 
been profited enormously from the developed analytical chemistry and computer science. 
Despite the pharmacokinetics of a drug can be studied individually in each subject, a 
population approach is beneficial for studying patient groups that are challenging to 
investigate, like premature infants, hepatic or renal impairment patients, etc. [2].  
Population pharmacokinetics, also referred as population PK or popPK, is the study that is 
defined when standard dosage is administered in patient population and the sources of 
variability in plasma drug concentrations is monitored between them. Measuring the 
variability between their characteristics such as age, weight, sex, race, renal function and drug 
interactions can support to modify pharmacotherapy [3]. Observing the population allows the 
exploration of the variability in pharmacokinetics that exists between the patients, for instance 
a patient taking a drug with renal impairment shows variations in drug concentration that is 
excreted in the urine [2], [4]. 
The population pharmacokinetics methodology assisted the achievement of better prescribing 
by the examination of drug concentration time data that is gained from scheduled therapeutic 
analysis. Pharmacokinetic parameters derived from population pharmacokinetics study such 
as clearance could assist in prescribing patients individually [2], [5]. 
Traditional pharmacokinetic is typically related to healthy volunteers where several samples 
are taken at specific times while population pharmacokinetic involve patients being treated 
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with different doses and obtaining blood samples at different intervals. The muddled blood 
sampling and dosing regimens result in sparse data of 3-4 samples from each patient [2], [3]. 
2. Pharmacokinetic Modelling 
Modelling and simulation are significant tools for incorporating data, information, and 
mechanisms to assist in reaching at sensible conclusions concerning drug development and its 
use. Figure 1 demonstrates a summary during the drug development procedure where 
modelling and simulation are frequently engaged. Building proper models can aid to analyse 
the time duration of exposure and response for multiple dosing routines [6]. An extensive 
implementation of population modelling methods can offer an outline for quantitating and 
monitoring variability in drug exposure and response.  
The term population pharmacokinetics denotes to mixed-effects modelling that is a 
combination of random effects (variance model) and fixed effects (structural model). Random 
effects parameters comprise of inter-subject variability and unexplained variability when the 
model is fitted to the data. On the other hand, fixed effects are parameters that include 
clearance and those factors that expressively effect clearance such as age and weight. 
 
Figure 1: Modelling and simulation during drug development [1] 
Models are the basic tool for understanding and explaining the time duration of drug exposure 
and response when multiple formulations or doses of a drug are administered to the subjects. 
It is also a mean of assessment of linked parameters such as volume of distribution and 
clearance. Population models could be comprised of a small number of observations from 
every individual and can be compared to the subsequent parameter observation that helps to 
define the consistency between populations or observations. It can also give the comparison 
between other drugs that are in associated therapeutic category to develop the possibility of 
new therapeutic drug. Thus, it can be concluded that the main aim of assessing population 
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modelling is to create a mathematical method which defines drug’s pharmacologic time 
course in the variety of doses assessed in clinical trials. 
Between-subject variability (BSV) in exposure and response is revealed in all drugs and the 
aim of their development is to identify and quantify this variability. For the improved safety 
and efficacy or appropriate controlling of variability in drug exposure it is important to 
understand the effect of factors that include weight, genotype, age, renal and hepatic function 
on exposure and response of drug [1]. 
Population modelling is a mean of identification and explanation of the association between 
the observed drug exposure and response and physiologic characteristics of individuals. 
Population pharmacokinetic modelling was first introduced in 1972 by Sheiner et al [5]. At 
the beginning, this method was introduced to work with the sparse pharmacokinetic data that 
was collected during the analysis of therapeutic drug but shortly it was widened to embrace 
models relating drug concentration to response such as pharmacodynamics [7], [8]. 
Subsequently, modelling is now significant measure in the development of drug. 
Population parameters were initially predicted by two approaches that include naive pooled 
approach in which the data of all subjects is fitted collectively by ignoring their differences, 
and two stage approach in which the data of each subject is fitted independently, and 
parameter estimated of each individual is combined to calculate mean population parameters. 
Both of these approaches carry intrinsic difficulties that get worse when deficiencies and 
errors are present such as missing samples or dosing compliance which eventually cause 
biased parameter estimates [9]. The Sheiner et al. method solved the problems related to the 
previous approaches and allowed the combination of sparse data of numerous individuals to 
evaluate between subject variability (BSV), population mean parameters and the covariate 
influence that identify and quantify variability in drug response and exposure. This 
methodology also generated SE which permitted a degree of parameter accuracy. 
The significance of each subject in population models is emphasized by estimation of 
variability, by recognizing the fluctuations in drug exposure with the variation of each 
covariate of the individual such as age or weight or consequent estimation of subject’s 
characteristics. The practice of pharmacometrics can expand the observation of the linear and 
saturable metabolism mechanism, notify to test the primary variety of doses, improve the 
dosage selection for subpopulations of subjects, and assess the study design precision [3]. 
2.1. Kinds of pharmacokinetic models 
Pharmacokinetic models define the concentration and time association. Compartment is the 
primary concept of all PK models that is defined by the body area in which the drug is 
kinetically homogenous and fully blends. Compartments are recognised as the universal and 
essential component of PK models but the models are described by the difference of how the 
compartments are linked. In different tissues, the equilibrium between the drug concentrations 
does not appear instantly. Therefore, the hypothesis of one-compartment model often 
becomes void. After the administration of few drugs, mammillary model is sometimes 
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essential to define the plasma concentration data mathematically [10]. Mammillary models 
usually comprise of central compartment that demonstrate plasma with some peripheral 
compartments interrelated to the central compartment by constant rates such as K12 or K21 
[11]. Often mammillary models have compartments that can be actual physiologic region e.g. 
extravascular fluid and blood but is not represented by any specific area of the body.  
Physiological based models have one or more than one compartments that demonstrate a 
distinct organ in the body with those organs that are linked with the blood flow [12]. 
Physiological based models usually require tissue and plasma concentrations and the 
parameters should resemble the literature values. However, mammillary PK models can be 
represented by blood or plasma concentrations only. Consequently, the application of 
physiological based models to clinical data is complex but it gives the understanding of the 
disease and physiologic effects in drug nature. It can also provide an opportunity to render 
preclinical outcomes to clinical surroundings. The simple mammillary open model is a two-
compartment model where the drug is introduced in both, central and peripheral 
compartments Figure 2. 
 
Figure 2: Two-compartment model. K12, K21 and K10 are first-order rate constants: K12 = rate 
of transfer from central to peripheral compartment; K21 = rate of transfer from peripheral to 
central compartment; ka = rate of absorption and k10 = rate of elimination from central 
compartment. 
 
 One-compartment model  
In one-compartment model, the central compartment (X1) consisting plasma or serum of 
blood that is used for sampling. The body represents kinetically homogenous division after 
the administration of the drug which means that the drug is distributed instantly all over the 
body and the drug rapidly equilibrates between tissues being highly perfused with blood such 
as heart, kidneys, lungs, brain and liver [13].  
 Two-compartment model 
In two-compartment model, the peripheral compartment (X2) consisting organs and tissues, 
the body is resolved into both central and peripheral compartments. It involves tissues that are 
not well perfused with blood such as fat, skin and muscle. After the administration of drug 
into central compartment, the drug is distributed in central and peripheral compartment but 
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the distribution is not instantaneous due to less perfusion of tissues [13]. Inter-compartmental 
distribution follows a first order process. 
 Multi-compartment model 
In multi-compartment model, the distribution of drug is into more than one compartment [13]. 
2.2. Meta-models 
Meta-analyses mean “the analysis of analyses” [14]. These analyses from numerous subject 
studies are potentially strategic analyses of collective results such as mean to incorporate 
outcomes and create summarised calculations. Meta models play vital role in the comparison 
of the efficacy and safety of novel therapeutics with those treatments that are missing 
individual data e.g. to compare the treatments with the products that are in competition [15]. 
They are also useful for the re-examination of the data from the studies that has mixed results 
[16]. Meta models can define the progression of disease or pharmacodynamics and are 
currently used commonly in the drug development to make the success or failure  decisions 
[17]. However, for the meta-analysis few steps should be taken into consideration such as: 
a) Before commencing the work, the aims and objectives of the studies must be outlined.  
b) The data to be used should be comprehensive, unbiased and compatible. Only the 
successful trials data should not be included. 
c) Between treatment arms variability and between subject’s variability must be defined. 
d) The aggregate data and individual data should merge sensibly like the method of 
combining the data should depend on the model [18]. 
The ambiguity of model is overlooked by the practice of choosing one model from a sequence 
of projected models and producing interpretations on the base of particular model. This could 
result in spoiled analytical presentation and ignore the better structures of other models. 
2.3. Bayesian model  
Bayesian model averaging is the practice of combining models and notifying the ambiguity of 
the model [19]. The Bayesian method is usually used in places where the drug has many 
models in the literature and the decision of choosing the appropriate model is not certain to 
evaluate novel study. The estimates of the accessible models can be definitely fitted and a 
particular model can be established which integrates many models. Consequently, the 
Bayesian model averaging approach permits the contribution of all the models for the 
simulation with the pre stated principles for the input to be decided according to the worth of 
the model or data and many other features [19]. 
2.4. Pharmacokinetic and pharmacodynamics models 
Pharmacokinetic and pharmacodynamics models are significant for associating 
pharmacokinetic information to clinical settings and involve drug effect [20]. Continuous 
pharmacodynamics metrics in models usually appear as a continuous function with 
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concentration effect bond. The concentration in pharmacodynamics model can be defined as 
direct drug concentration in central compartment or as indirect in which the response of 
pharmacodynamics lags after the drug concentration in plasma. The discrete effect of 
pharmacodynamics models uses logistic equations frequently to transform the influence to a 
probability in individuals that can be linked to pharmacokinetic model. These discrete 
pharmacodynamics effects include treatment, success or failure and the adverse effects. The 
class of pharmacokinetic and pharmacodynamics models are exposure response models in 
which instead of time, a metric that defines steady state drug exposure is an independent 
variable such as maximum plasma concentration (Cmax), area under the curve (AUC) and 
dose. 
2.5. Population model gears 
Population modelling demands precise information of covariates, dosing and measurements. 
These models include number of components such as stochastic models, covariate models and 
structural models. Stochastic models demonstrate the random effects or variability in the data 
evaluated [21]. Covariate models define the effect of factors like time course of response in a 
disease or demographics of individual while structural models are demonstrated as differential 
or algebraic equations and define the measured response time course. 
 
Advantages Disadvantages 
Pharmacokinetic analysis generally include 
individuals taking drugs 
Comparatively large number of patient is 
involved ( more than 40) 
Can deal flexible study designs that take 
place during treatment 
Difficult pharmaco-statistical analyses 
Few samples are required from each patient 
involved in the study 
 Compilation, collection and verification of 
large amount of data is required 
Opportunistic sampling could be cost-
effective 
Building model could be tiresome, time 
consuming and labour intensive 
Quantification and screening of covariates for 
determining variability is needed 
The diagnostics of models can be complex 
and time consuming 
Inter-individual and intra-individual 
variability can be differentiated  
Problems with controlling missing data such 
as all covariates in every patient 
Modelling software is easily accessible such 
as NONMEM and R  
 
Table 1: Advantages and Disadvantages of population pharmacokinetics modelling 
3. Population methods 
Population pharmacokinetic modelling approach is practiced in groups that are comprised of 
more than 40 individuals. In this study, instead of individuals, population is evaluated. 
Patients taking different doses on different timings are sampled. Population pharmacokinetics 
can predict oral bioavailability and the drug clearance. The most repeated value (mode) is 
usually used as a parameter which helps to achieve mean of population with the increase of 
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patients. Therefore, in population observation, the information gained by each individual is 
used to evaluate their potential value of parameter. The accuracy of these parameters depends 
on extent of data estimated from each individual and on the difference between their predicted 
values and standard population value.  
Population pharmacokinetic approach is not a substitute method for the existence of sparse 
data or model building with many covariates because there are limitations in dealing with 
observed sparse data in population method. For instance, more than one data point should be 
available from each patient else there will be mystified inter individual variability. It is 
claimed in clinical perspective that a covariate should be included in a model only if it 
sufficiently decreases the pharmacokinetic variability to alter the prescribing. For instance, in 
the modelling gentamicin pharmacokinetics, renal function must be involved. When there are 
more than two covariates present in a model such as age and sex, the problem of masking rise 
in defining the source of variability and ultimately these complex models increase the errors 
in prescribing and are difficult to practice clinically. 
4. Application of population pharmacokinetic models 
Population pharmacokinetic modelling is labour extensive, time consuming and a complex 
method [22]. Population pharmacokinetic model gives the appropriate prediction of unknown 
but accurate values of pharmacokinetic parameters like all mathematical models. Plasma 
concentrations estimated in the model are uncertain up to some extent due to the ambiguity 
involved in the true value of the evaluated parameter from a data in which model is fitted. 
According to a saying it can be said that ‘all models are wrong, but some are useful’. 
Population evaluations have several beneficial clinical applications like in those subjects for 
whom traditional pharmacokinetic analyses is hard due to difficulty in recruiting, such as 
patients under intensive care or infants. 
Population pharmacokinetics is enormously practiced in Australia and has the possibility of 
better-quality clinical results by prescribing individually [23]. For instance, population 
pharmacokinetics approach is used to create a dosage nomogram for caffeine treating infants 
affected by apnoea of prematurity [24]. 
Population pharmacokinetic approach is a developing and significant measure of drug 
development, clinical and pre-clinical studies, and for investigation of post marketing. The 
pharmaceutical industry reveals outstanding reviews [25] and regulatory perspectives [26], 
and web based guidelines generated by regulatory agencies [27], [28]. However, these studies 
are playing great role in clinical application and research in an extensive range of patients and 
situations such as clotting disorders [29], serious infections [30], diabetes [31], pregnancy 
[32], malignancy [33], organ transplantation, arthritis, self-poisoning [34] and apnoea of 
prematurity [24], [35]. 
Many aspects should be taken into consideration for the pharmacokinetic model evaluation. 
The parameter estimation usually differentiates models that are at initial stages of 
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development and eradicates inadequate models. For further stages, simulation based 
approaches like visual predictive check (VPC) are beneficial when models with limited 
subjects are evaluated in final model [36]. For model diagnostics, Karlsson and Savic have 
given tremendous evaluation [37]. Model evaluations must be opted for the satisfaction and 
surety of the suitable model for proposed use.  
5. Population pharmacokinetics modelling methodology 
Population pharmacokinetics is the study of population where each individual is assessed 
simultaneously with nonlinear mixed effects model refers to the parameterization. Nonlinear 
mean that the variable which is dependant such a concentration, is related to the associated to 
independent variables and model parameters nonlinearly. Fixed effects refer to the parameters 
that do not change in individuals while random effect refers to those parameters that change 
through individuals. 
The main aim of population pharmacokinetic modelling estimations is to look for the 
parameters of population pharmacokinetic and source of variability. The rest aims consist of 
observed concentrations of the dose administered by detecting the predictive covariates in 
evaluated population. Like single subject analysis, population pharmacokinetic approach does 
not demand scheduled time for sampling nor many observations from each individual. 
Therefore, few observations from each subject or sparse data and combination can be 
analysed. 
The main five key parts for building a pharmacokinetic model include; data, structural model, 
statistical model, covariate model and modelling software. Structural models define the 
concentration time course in the subjects. Statistical models describe random variability in 
population that not explainable such as between occasion variability, between subject 
variability or residual variability. Covariate models demonstrate variability that is estimated 
by the characteristics of the population such as covariates. Modelling software such as 
nonlinear mixed effects modelling software combine data and models and apply the method 
of estimation to evaluate parameters for the statistical, structural and covariate models which 
define the data [38], [39]. 
5.1. DATABASES 
Population analysis requires appropriate production of databases that is the most critical and 
time consuming part of the analysis [1]. To ensure the accuracy of the data, it should be well 
inspected. Before modelling, the graphical examination of data can detect possible errors and 
problems. Data records could reveal errors during the beginning of model evaluation or 
during data cleaning such as temporary or rapid fall of concentration which can be observed if 
they warrant an error that could harm the development of model. 
Every evaluation consists of a lower concentration limit, in which the concentration could not 
be calculated appropriately if it is below that limit. On the calibration curve, the lower limit of 
quantification (LLOQ) is considered as the lowest standard which is 80-120% accurate and 
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20% precise [40]. The data below the limit of quantification (BLQ) is the data that is below 
the lower limit of quantification. If there are any samples in the data that are below the limit 
of quantification then the data detected close to the lower limit of quantification is normally 
censored. The effect of censoring can be observed by adding the line lower limit of 
quantification horizontally on plot of concentration vs. time. However, many studies show 
that the influence of censored data changes according to the circumstances when dealing with 
the below the limit of quantification data in population modelling [41]–[44]. Censoring could 
interpret variations in the outcomes when practised on the same data as population modelling 
approaches have more strong impact of censoring by lower limit or quantification than the 
methods of non-compartmental studies. 
5.2. Structural model 
Structural models have allegations for the selection of covariates [39]. Hence, evaluation of 
structural models should be cautiously done. The structural model is equivalent to an 
absorption model that defines the distribution of drug in blood for extravascular dosing and 
systemic model that defines kinetics after intravenous dosing. Mammillary compartment 
models take superior place in the literature, although pharmacokinetic models based on 
physiology play vital and developing role [12], [45].  
Concentrations generally display one, two or three exponential phases when a particular part 
of the body gives data, which ultimately can be presented by systemic model with one, two, 
or three compartments respectively. By the plot of log concentration vs. time, the 
understanding of suitable compartment could be accomplished. When log concentrations 
decrease or increase with steady state in constant rate infusion, every distinct linear phase will 
require personal compartment.  
Models with fewer compartments do not define the data accurately and ultimately illustrate 
bias in residuals vs. time plots while models with excess compartments display slight 
parameter estimation enhancement for increasing the number of compartments. Thus, the 
selection of number of compartments should be sensibly done. For extra peripheral 
compartment, parameters will meet the plasma concentration values that have slight influence 
such as low inter-compartment clearance CL and high volume or vice versa; or the parameters 
could be evaluated inappropriately. A significant attention should be paid to the accurate 
prediction of first order elimination. The rate of elimination in first order system is 
proportionate to concentration whereas clearance is constant. 
The law of superposition illustrate the concept of increase in concentration with the increase 
of dose [6]. On the contrary, the rate of elimination is not dependant on concentration for zero 
order systems. Concentrations will rise by more than two folds when dose is doubled, as 
clearance in dependant on dose. With the rise of concentration, elimination progressively 
transfers to zero order state from first order state and saturate the elimination passages. To 
measure saturable elimination, pharmacokinetic data gathered from the population received 
single dose of drug is hardly enough, hence comparatively high range of doses is required. If 
steady state kinetics is not able to be estimated from single dose data then multi and single 
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dose studies both show saturable elimination. Indication of nonlinearity could be revealed by 
non-compartmental or graphical studies like, dose-normalized AUC dependant on dose, dose-
normalized concentrations that cannot be superimposed, multi-dose Css or AUCτ which is 
greater than estimated by single dose clearance and area under the curve. 
For one compartment model and described rate of dose, saturable elimination is typically 
depicted by Michaelis–Menten equation [6].  
𝐶 =
𝐴
𝑉
 
dA
dt
= dose rate − (
Vmax ∗ C
Km + C
) 
where dA/dt show rate of change in the amount of drug, Vmax is represented as the maximum 
rate of elimination and Km depicts the concentration related to semi Vmax. When C is less 
than Km, the rate converts to Vmax/Km*C in which Vmax/Km is inferred as the apparent 
first order clearance but when C in greater than Km, the rate comes to be Vmax in which it is 
interpreted as apparent zero order clearance. The extensive interrelation of Vmax and Km can 
make the estimation challenging for both as random effects parameters such as the segment of 
between subject variability. Generally Vmax is assumed as a function of accessible amount of 
elimination enzymes or transporters while Km is assumed as a function of the structure of the 
eliminating enzyme or transporters and drug.  
The saturable elimination involvement into plasma concentrations must be analysed prudently 
in the areas of drug elimination, framework of drug and in the route of administration. As 
example, saturation in active tubular reabsorption drugs increases renal clearance and lower 
concentrations under the anticipated values from superposition whereas saturation in active 
renal tubular secretion lowers renal clearance but rise concentrations above the predicted 
value from superposition.  
The bioavailability (F) is defined by the fraction of the dose that is administered by 
extravascular routes and goes into blood stream. The drug that is not absorbed by the body 
does not influence blood concentrations and consequently the resultant concentration appears 
lower due to the absorption of fraction of actual dose (F). The amount of drug absorption is 
dependent on the route of administration. However, it also can be influenced by the absence 
of physical entrance of drug in body for instance the residual of per os dose in gastrointestinal 
tract, during absorption transformation to a metabolite like drug cleared hepatically, 
accumulation or precipitation at injection area or a slow absorption component that is 
identified during study plan such as subcutaneous administration to lymphatic uptake of 
compounds.  
Absolute bioavailability is referred as complete availability of dose such as from intravenous 
administration where F will be 100%. It can be predicted only with the simultaneous 
existence of intravenous and extravascular data. 
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5.3. Statistical model 
The statistical model defines variability in the structural model. In pharmacokinetic model, 
the basic sources of variability are between-subject variability (BSV) and residual variability. 
The BSV shows variation of parameter in the subjects while the residual variability (RUV) is 
the variability that is not described when other sources of variability are monitored. Between-
occasion variability is also expected by some studies in which the administration of drug in 
each individual takes place on more than two occasions that could be divided by adequate 
interval for the variation of fundamental kinetics in between the occasions. It is significant to 
build a proper statistical model for covariate estimations, simulations, appropriate use of 
models and to demonstrate the extent of residual variability in the data [6]. 
Residual variability results from numerous sources such as the model misspecification, assay 
variability, and miscalculations of sample time collection. As between-subject variability, 
residual variability model is selected on the basis of the nature of data to be estimated. 
5.4. Covariate model 
In pharmacokinetics calculations, it is important to identify the covariates that can predict the 
variability of pharmacokinetic. The potential covariates are generally selected by the class of 
drug, physiology or the identified properties of drug. For instance, drugs that are extremely 
metabolized contain the covariates commonly like genotype, weight or liver enzyme. The 
covariates should also go through the preliminary evaluation as the extensive run time could 
create a problem. Thus, the number of covariates in the model must be limited. Covariate 
screening can decrease the amount of evaluations using comprehensive additive models, 
techniques dependant on regression, or by correlation analysis that estimates the significance 
of covariates selected. Covariates are distinctly verified without covariate screening and all 
covariates are involved which are according to the required measures. The covariates 
identified in screening are individually evaluated with screening and the related covariates are 
all incorporated. The selection of covariates for nested models depends on the parameter 
estimation and likelihood ratio test (LRT). Hence, the specified levels in advance such as P < 
0.01 or greater are set before the model based evaluations and the statistical significance can 
be caused by covariate effects. Then covariates are deleted backwards and fluctuations are 
analysed by LRT at tough criteria of parameter estimation. This method ends after the 
testation of all covariates and additional simplification of final model. 
The inclusion of just statistically significant models in the model can create selection bias by 
practising stepwise method in model building. These models can result in exaggeration of 
significance of selected covariates. Multiple covariates evaluation with the extreme or 
moderate correlation such as weight and creatinine clearance can also cause selection bias that 
ultimately halts the true covariates discovery.  
If values are continuous in sequence, extent and substance, covariates will also be continuous. 
On the other hand, if values are not connected and distinct or establish different classes, 
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covariates will also appear distinctly which should be dealt differently. Both data should 
guarantee the physiological results by the parameterization of covariates.  
5.5. Modelling software 
There are number of available population modelling software. The selection of the appropriate 
package should be taken into attention considering the support for package, awareness of 
users with the package and the extent of package reputation with the regulatory reviewers. 
Many pharmacometricians are experienced in few packages (just one or two). The idea of 
parameter estimation is implied by most packages in order to reduce an objective function 
value (OFV) by practicing maximum likelihood estimation [6]. The calculation of the 
likelihood is much complex in population modelling than only fixed effect models [6]. At the 
time of population data fitting, the concentration estimated for each individual is influenced 
by the variance in population parameters and each individual parameters, and the variance in 
each values of predicted and observed concentrations. The evaluation of marginal likelihood 
depends on the random effect (η) and fixed effect population parameters. There is no 
existence of analytical solution for marginal likelihood. While looking for maximum 
likelihood, numerous approaches were applied for the approximation of marginal likelihood. 
FOCE and LAPLACE are the older approaches that estimate the true likelihood with 
additional simplified function [46].  
Recent approaches such as SAEM contain stochastic elimination and filtering approximations 
partly by iteration of trial and error. Every approach of estimation comprise of pros and cons 
such as stability in over parameterized models and accuracy of parameters and complexity of 
primary parameter predictions [47], [48]. In nonlinear mixed effect model, the estimation 
method of original first order is of concern that results with biased estimations of random 
effects. The estimation methods and the difference in their approaches are often considerable. 
However, it is sensible to apply two or more methods in the early phases of model building 
such as, by estimating goodness of fit with stimulated or predicted data.  
 Modelling with R 
R is open source software environment and data analysis language for statistical computing 
and graphics. It can be run on diversity of Windows, MacOS and UNIX platforms. It can be 
downloaded from http://www.r-project.org. Multiple online learning sources of R are 
available. R software provides the combined collection of facilities to calculate, manipulate 
and display data graphically. It also offers the facility of: 
 Data storage and handling it effectively 
 Numerous operatives to evaluate groups, particularly matrices 
 An integrated and rational suite of tools that aid in effective data analysis 
 Service of graphical data analysis that can be displayed on the computer directly or 
can be provided as a hardcopy. 
 Offers a programming language (“S”) which is an effective and well-built to deal 
loops, user defined recursive roles, facilities of input and output and conditionals.  
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R is a mean of novel emerging approaches of interactive data analysis and its rapid 
development has been expanded by a huge list of packages.  Nevertheless, programs in R are 
temporarily written that are for only one study of data analysis. 
Population models play an essential part in the regulation, development and appropriate use of 
pharmaceuticals [6], [49]. Nonetheless, the methods are really time-consuming to make 
predictions from population models and left the enthusiastic pharmacometricians with the use 
of special software that concise it’s broader implication [50]. The flexible and sophisticated 
model output and data plotting are conceivable by the latest developments like ggplot2 
package [51], [52] for the statistical language [53] and R data analysis. The models are 
required the process of re simulation and manual update to inspect different values for model 
parameters.  
Advances in R and its packages specifically Shiny package have given an opportunity to R 
operators to display the output to web browsers for R [54]. Shiny, established by Rstudio is a 
package for R that can be installed in R or Rstudio. The installation of packages in R has 
numerous ways and the installation depends on the R interface and user’s operating system. 
RStudio that is an integrated development atmosphere for R can be installed from 
http://www.rstudio.com/. To install packages, Tools and install package can be used. Further 
dependencies of the package will be installed automatically by RStudio.  
The broad spectrum nature of R language has allowed the programming of interactive 
pharmaco-metric models with the package of Shiny that ultimately creates a web- browser 
interface which is accessible by internet access on the any computer. Some tools developed 
by Shiny package and R comprising R code can be seen without the installation of R 
software. These include such applications that are meant to educate students at high school or 
a tool related to the population model simulation along with simulated variability. To operate 
R and Shiny package, just prior knowledge of R language is needed which is more 
complicated in other methods of web page designing. Berkeley Madonna’s software gives an 
access to substitute method that enables the models to specify as differential equations and the 
by the usage of sliders and radio buttons, simulated results for different parameters are 
presented [55]. This main objective of Berkeley Madonna is continued by R and Shiny that 
gives reactive update of output with the change in input by the help of widgets. Due to the 
blend of extended packages and flexibility in R language, the pharmacometricians are able to 
regulate the coding every component of a population model, attained output and the look of 
the user interface for the application. However, learning R and Shiny simultaneously is not 
suggested. 
 Shiny Application 
Building of Shiny applications require two R scripts that have an interaction in between them; 
 A server script that is named as server.R (can be renamed as required) that integrates 
commands for the data processing, user input and output with the means of R 
language and from installed packages functions 
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 A user-interface script is named as ui.R that regulates layout and appearance of the 
application. 
For the learning of Shiny applications, RStudio has introduced tutorials and exercises on the 
website of Shiny [56]. These tutorials are supported by the articles defining Shiny skills, the 
pages of references for Shiny functions and a list of examples containing code. RStudio has 
also referred eleven built in examples in Shiny package. It is compulsory to install Shiny 
package and its dependencies to run the Shiny applications in RStudio or in R and the 
required R scripts (ui.R and server.R) must be present in the same directory. To present the 
application from RStudio, ui.R and server.R scripts are needed to open on RStudio and the 
function of ‘RunApp’ present in the top right corner should be clicked. To launch the 
applications from R, working directory is required to set at the place of application folder and 
at the end RunApp option is required to use. Ultimately, a Web browser window will be open 
by Shiny where everything will be displayed.  
 User-interface (ui.R) 
There is number of built-in widgets and modifiable layouts for applications in Shiny which 
enables the effortless and easier building of user-interface. Creators can choose any of the 
existing options of layouts that are adjustable to the sizes of different browsers of devices 
such as computer, phone and tablet. The tabs or sidebars can also be included that distinguish 
the input and output. Any alteration can also be made on the displayed layout after meeting 
particular conditions of input. The ui.R scripts include the code that instruct the layout of 
application, its appearance, widgets of input such as sliders, check boxes, buttons, selection 
boxes and so on, and the output. The basic components that define the user-interface of the 
application are; 
fluidPage(fluidRow(  
h2(“Heading”), 
plotOutput(“plotCONC”),  
sliderInput(“Title”, “Covariate:”, min = ‘value’, max = ‘value’, value = ‘value’, step = 
‘value’), 
align = “center”)) 
In the layout function, all code required for the user-interface contents should be in the 
brackets. The functions of layout (as stated above) like fluidPage is required to make a canvas 
for the interface and fluidRow is used to position the widgets of the user-input such as 
sliderInput is used to generate a slider and plotOutput function is needed to plot an object. 
Every function of layout possess its outline for placing elements while other functions such as 
fixedPage and navbarPage depending on their functions are capable of creating pages with 
different designs. Nevertheless, each function follows the similar classified structure in which 
the functions like sliderInput or widgets are placed in a layout function of fluidPage and in a 
positioning function of fluidRow. The same level functions are placed in sequence that are 
separated by “,” within their higher level function. 
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If there is any error from Shiny or R packages, the message of an error will prevail at the time 
of opening the application in the Web browser and after closing the application it will be seen 
in the R console. The evaluation of the appropriate opening and closing of the brackets prior 
to initiation of the application can aid to avoid error messages. After getting a detailed ui.R, 
functions written at the beginning in the script become more complicated to detect. For this 
problem free source code editor software or RStudio can help at the time of writing code as 
they highlight any error made such as unclosed brackets. The minor errors can be detected by 
these functions but if there is an existence of a major error with a non-functional application, 
a Web browser page will be displayed with the grey colour. Generally, other messages 
relating to error give a number of the line where the code is written or provide the name of 
function in question. While evaluating the pharmacometric model coding, it is sensible to 
write a generic R script to confirm its successful working before integrating the model in 
Shiny application. 
The arrangement of server.R code has a critical impact on illustrating commands for the 
application whereas it enhances the speed or application and reduces unnecessary 
computation. The ShinyServer function needs input and output object from ui.R. Objects that 
are influenced by the input widgets present in ui.R e.g input$KA, are called “reactive”. 
Whenever there is change in input from a widget, reactive object also changes its value 
accordingly. To process and describe the reactive objects, the related expressions should be 
written in a render* function in order to get a reactive output to ui. The term (*) represents the 
description of the output object such as a text, plot or a table. By the render* function, a 
reactive expression used to deal with a list of reactive data frames which could be directed to 
user-interface.  
The function of renderPlot that comprise of input objects such as (KA and V), calculation 
expressions for concentration and ggplot2 [52] to plot concentration vs time (plotobj), will 
update to reflect the change of every widget and the updated plot object will be saved for the 
output object as plotCONC. It is recommended to enclose code within ShinyServer and 
render* functions to avoid the sluggish speed of the application due to detailed code. At the 
start of the script, code is run just one time when the application is commenced, it does not 
require running every time with the change of widgets. Thus, it is considered an ideal area to 
load libraries, datasets, define constant expressions or source code. All of the functions and 
libraries could also be saved in another script that is named as ‘global.R’. 
The code written in ui.R script is called in sequence by Shiny (from left to right and from top 
to bottom). The layout function arranges the elements in sequence and the user-interface show 
the elements accordingly.  
fixedPage(fixedRow(  
column(10, h2(“Title?”, align = “center”), offset = 1)), 
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Above is the example of code that defines the layouts. A fixedPage layout aligns elements in 
a fixed width and in rows and columns such as widgets and output text or plot. FixedRow 
command show the elements in a same line and the column command allows the space 
horizontally and the elements are ordered in a wide grid of 12 units. However, fluidPage and 
fliudRow organize the page layout according to the browser dimensions in which the 
application in open. Each element is given a width and a column. If there are more elements 
to be added, they should be written under the heading with a new row by using fixedRow and 
column similarly as above while the dimensions can be defined according to the requirement 
of the content. The layout fixedPage is not restricted to fixedRow function, similarly 
fluidPage and fluidRow act in a same way. The utilization of sidebarLayout in the application 
forms a sidebar that appears as a bordered part in a user-interface along with a background. 
sidebarLayout can arrange the elements to the sidebar with the function of sidebarPanel or by 
mainPanel function to an unformatted area, instead to assigning elements into columns. There 
are other functions for layout such as tabsetPanel and navlistPanel which make the sections of 
the user-interface e.g. tabs on the navigation list divided for different tables and plot that can 
be mixed-up if not separated [56]. 
The widgets are elements that are interactive and give the users an opportunity of exploration 
of different categories or values of variables or parameters. The selected values are stored by 
the widgets and called by the server.R, render* functions or reactive function process them for 
output which ultimately are directed to the user-interface for the presentation. Hence, if a 
widget is changed, the value called by server.R will also change followed by the change in the 
output. There are plenty of prebuilt widgets combining R functions and an analytical thread of 
arguments in Shiny package.  
The help can be acquired by writing in R the symbol “?” and then writing the name of input 
function of a widget (e.g. ?fixedPage). Each function of widget is named in order to be called 
by server.R from ui.R that is not visible to the users while a label argument that is also 
important to write, is visible to the user. To complete the function, other arguments required 
depend on the type of widgets such as selections for selection boxes and for sliders min, max, 
value and step values. Some widgets have advantage over others that they confirm users can 
select only possible values by limiting the biological possibilities or by restricting the code in 
server.R. The example of the widget code in ui.R for the selection box for dose frequency in 
sidebarPanel is presented below: 
sidebarPanel(selectInput(“FREQ”, “Drug Frequency:”,  
choices = list(“Once a day” = 1, “Twice a day” = 2, selected = 1)), 
This code will create a selection box by the selectInput function. “FREQ” is the name of 
widget that will be called by the server.R as input$FREQ. the user-interface label here will be 
“Drug Frequency”. An argument is also needed for choices such as a list of labels assigned to 
the numbers. It is modifiable and ‘selected’ can be included which is the allocated number to 
value from choices to be displayed on initiation of application. It can also allot the box width 
in pixels and give option for multiple choices. On the other hand, a slider widget can also 
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provide these limitations in which the user can only slide the bar to the available values such 
as 1 = once a day, 2 = twice a day and so on. The example of code required for the slider is as 
follows: 
sliderInput(“FREQ”, “Drug Frequency:”, 
 min = 1, max = 2, value = 1, step = 1), 
Rather than a slider, a selection box can give a precise classification by the help of text. 
Widget selection should be made on the basis of user audience concern, capability of 
communicating the aim and kind of variables to which it will attach such as categorical vs. 
continuous. The variety of widgets can mess the user-interface easily, thus it is recommended 
to limit the free availability of widgets by the user. For this purpose, an option provided by 
Shiny can be used that has an ability of concealing or displaying elements of widgets for 
particular situations with the usage of renderUI in server.R and conditionalPanel in ui.R. The 
example of conditionalPanel in checkboxes is as follows: 
conditionalPanel(condition  =  “input.FREQ == 2”, checkboxInput(“Drug1”, “Missed on 
2
nd
 Day:”, value = FALSE), checkboxInput(“Drug2”, “Drug Doubled on 3rd Day:”, value =  
FALSE)), 
The conditionalPanel has a condition argument that is assessed frequently to decide the 
display of the following elements. However, these two conditionalPanel checkboxes will be 
displayed only when the selection box widget (Drug Frequency) will be selected as 2. The 
checkbox widget doesn’t have numbers, thus the value argument relating to the first input is 
only dealt by TRUE and FALSE, if it is TRUE, the output will be affected while FALSE 
doesn’t influence the output anyway.  
The other types of widgets include radio buttons (radioButtons) that are most used in 
pharmacometrics, downloadbuttons (downloadButtons), and slider ranges in which two 
values can be selected on the ends of slider (sliderInput). 
Heading (h) are the functions in Shiny used to define the heading and like widgets, they are 
coded in layouts in a fixedRow (positioning function).  The heading can be made in variety of 
sizes and the code used for the size is h1, h6 and p. The first level of heading is largest (h1), 
the sixth level header is the smallest (h6) and text paragraph is generated by (p). The align 
argument is used to set the alignment of heading as illustrated below: 
h2(“Title”, align = “center”) 
Breaks coded as br() and lines coded as hr() are used in the application to make a partition of 
the heading and the functional elements. They both can adopt the level of positioning 
functions (fixedRow) or similar to widgets. 
*Output functions in Shiny call from server.R the objects that are reactive to the user 
interface. (*) in *Output describes an object i.e. table, text or a plot. In the user interface, they 
are constructed in an order similar to widgets by writing the function *Output in the user 
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interface script in a positioning function. Following is a ui.R code where a reactive plot is 
included in the mainPanle by the use of plotOutput which accordingly updates with a widget 
change:   
mainPanel(plotOutput(“Output argument”, height = ‘value’, width = ‘value’)) 
The reactive object should be named to identify each *Output function when called by 
server.R. Labels cannot be assigned to *Output functions and output objects names are not 
visible to the users. Thus, in server.R, for the reactive object titles or headings are required in 
the expressions while in ui.R heading element is needed to build. Every *Output function can 
possess a particular argument due to its individuality such as plotOutput the arguments of 
height and width for specifying the plot dimensions. Other *Output functions own the names 
that define their goal such as imageOutput, tableOutput, uiOutput, htmlOutput and 
textOutput.  
6. Pharmacoeconomic model 
Pharmacoeconomics is related to the scientific authority where the value of drug therapy or 
pharmaceutical drugs is compared [57], [58]. The study of pharmacoeconimcs assesses the 
pharmaceutical products in terms of finance by its cost, effects, or efficacy. This study assists 
in leading scientifically towards the means of ideal allotment healthcare. Pharmacoeconomics 
emphasis on the pharmaceutical evaluation economically by practicing cost benefit analysis 
(CBA), cost utility analysis (CUA), cost minimization analysis (CMA) and cost effectiveness 
analysis (CEA) [59]. The quality adjusted life year (QALY) is a main health outcome of 
importance in pharmacoecomics evaluations that involves quantity and quality of life. Cost 
per QALY analysis is practiced by many studies. Economic evaluations of pharmaceuticals 
are progressively practiced and are executed in conjunction with the randomized controlled 
trials and decision analytic modelling approaches. The healthcare deciders focus and 
recognize the money value from healthcare interferences.  
Pharmacoeconomics method plays a vital role in the economic assessment of several 
treatment decisions. The main complication associated to economics is scarcity that means it 
limits the choices for the allotment of healthcare funds. If the expenses in one region of 
healthcare are high, it will definitely affect the expenses to be made in other region with the 
limit amount. The economists use the method of prediction for the advantages by opportunity 
cost. Pharmacoeconomic evaluation method gives a prospect of defining the treatment options 
by estimating the amount of income to attain highest health benefit by money spent per unit, 
which can be gained by accessing opportunity cost of apportioning resources to a specific 
option of treatment. 
With the development and licensing of costly pharmaceuticals, pharmacoeconomic evaluation 
prove to be extremely beneficial particularly for the developing countries where scarcity 
obstacles the resources for the implementing the ideologies of pharmacoeconomics for 
different treatment options and drugs. It is imperative in order to gain lowest cost with the 
maximum progression in the quality of healthcare and life [60]. 
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6.1. Methods of pharmacoeconomics  
Pharmacoeconomic evaluation methods are all similar in terms of evaluating input cost and 
the benefits achieved from the intervention of a drug [61]. Rather than just adding the cost of 
the drug, direct and indirect both costs are included in the price of drug therapy where direct 
costs are referred to the capital and staff cost whereas indirect costs may contain the losses 
related to the earnings and productivity or traveling costs to the hospital. A number of the 
costs are not easy to evaluate such as imperceptible costs for any discomfort or pain that is 
suffered by the patient. The variance among economic evaluations is stated in terms of extent 
of advantages as costs can only be defined in monetary form. The measurement of such 
advantages can be done in natural units like saved years of life by antiretroviral therapy or 
lipid lowering. The advantages can also be evaluated with regard to utility units like quality of 
life which include the physical activity evaluation such as psychosocial results like anxiety 
and mobility extent. 
 Cost benefit analysis (CBA) 
The cost benefit analysis measure the costs and benefits both in terms of monetary for the 
drug. This approach allows the evaluation of the expenses occurring in health area versus the 
expenses incurring in additional areas such as transportation and education. Due to an ethical 
opposition for giving importance to the monetary value instead of human health and life, 
some cost benefit educations are established. Nevertheless, monetary values are practiced for 
predicting the death or injury compensation in terms of health.  
The perspective of interrelated decision makers is fundamentally required for the economic 
evaluations report. To meet the requirements of individual prescribers and governmental 
judges, the existing evaluation might be needed to analyse diversely. The social viewpoint 
may comprise of direct costs and indirect medical costs e.g. hospitalisation and drug prices 
(direct) and pain and productivity (indirect). Although, only direct costs are analysed by the 
viewpoint of main healthcare manager such as expenditures related to drug therapy, general 
practitioner consultation and laboratory observation. The social perspective of policy 
regulators is taken into attention as the economic analysis objective is to utilize the resources 
appropriately but the healthcare provider with a limited finance would ponder the additional 
costs of drug with more preference.  
Multiple healthcare interventions are compared to gain the maximum benefits but the 
investment of healthcare resources could prevail with different schedule as compared to the 
benefits gained such as the comparison of precautionary therapies (statins with curatives) e.g. 
thrombolysis. Generally, benefits are aimed prior to any investment and to consider this 
optimistic time priority, upcoming consequences and costs are discounted in economic 
evaluation in order to show values by around 5% annual rate. 
In economic evaluation, the adaptation of discount rate is only a suspicion where other 
uncertainties emerge with the deficiency of accuracy in costs and benefits analysis. The 
method of sensitivity analysis is practiced to handle these suspicions that also include 
modification of basic parameters and expectations to define their influence on economic 
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evaluation. In an organized setting of clinical trial, the efficacy of an intervention might 
exaggerate the effectiveness in regular clinical practice. The cost effectiveness will be 
difficult to retain if the event rate is 15 % while the lipid lowering cost effectiveness over 
specific time duration has 25% decline in coronary event. Thus, in economic evaluation, 
sensitivity analysis is obligatory to analyse the influence of analytic assumptions  [62]. 
 Cost minimization analysis (CMA) 
Cost minimization analysis is very strict type of analysis that attentions completely on costs 
such as health services. Subsequently, this analysis is helpful in the similar health outcomes 
gained from two separate treatments which are required to be analysed individually. For 
instance, choosing the introduction of a generic drug instead of the branded that will give 
equal benefits with minimized costs. Generic prescribing is a great source of boosting cost 
effectiveness. Doctors gained an opportunity of easily understanding and implicating such 
kind of analysis extensively. Nevertheless, the therapies and programmes directing to altered 
outcomes cannot be evaluated by this form of evaluation [62], [63]. 
 Cost effectiveness analysis (CEA) 
Cost effectiveness analysis is a term that is usually roughly used to denote every type of 
economic analysis. However, it appropriately discusses a specific type of evaluation where 
costs are stated in monetary terms and health benefits are estimated in terms of natural units 
such as saved years of life. Consequently, cost effectiveness analysis involves more than two 
therapies that have common objective of treatment but reveal different rates of efficacy. For 
example, if in severe reflux oesophagitis the aimed outcome is symptomatic aid, we can 
analyse the costs of each relieved patient with proton pump inhibitor comparing to the ones 
who use blockers of H2-receptors [62], [64]. Cost effectiveness analysis is widely practiced in 
economic evaluations still it is not ideal to apply this approach to compare completely 
different therapies having different benefits.  
In the comparison of therapies the resource allocation evaluates the quantity of benefit 
obtained for the cost experienced. Therefore, the calculation of incremental cost effectiveness 
of each therapy is significantly required. Below is an equation that explains the incremental 
cost effectiveness ratio of one therapy (1) over another (2).  
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑟𝑎𝑡𝑖𝑜 =
𝑐𝑜𝑠𝑡 (1) − 𝑐𝑜𝑠𝑡 (2)
𝑒𝑓𝑓𝑒𝑐𝑡 (1) − 𝑒𝑓𝑓𝑒𝑐𝑡 (2)
 
𝐼𝐶𝐸𝑅 =  
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑐𝑜𝑠𝑡𝑠
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑒𝑓𝑓𝑒𝑐𝑡𝑠
 
The cost effectiveness (CE) plane is a significant measure used in cost effectiveness analysis 
and broadly applied in healthcare sector. The objective of cost effectiveness plane is to 
demonstrate the comparison in costs and effects between medical interventions, medical 
treatments or both combined. It aids in making sensible decisions by evaluating different 
strategies. 
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Figure 3 : Cost effectiveness plane 
The cost effectiveness plane determines the results of incremental cost effectiveness ratios 
analysis Figure 3. The second quadrant (Q2) demonstrate the high effectiveness and low cost 
of interventions which is dominant and results in the acceptance of the interventions while 
quadrant four (Q4) shows an area of rejection as it comprise of high cost and low 
effectiveness. Interventions in quadrant three (Q3) may be considered by developing countries 
as it has lower cost but also low effectiveness. On the other hand, developed countries 
normally consider quadrant one (Q1) in which new interventions result in high effectiveness 
and higher costs too.  
 Cost utility analysis (CUA) 
In cost utility analysis, the effects of therapy on quality of life and patient wellbeing are both 
measured in common unit. It is identical to cost effectiveness analysis where the outcome is 
predefined and the cost incurred is expressed in terms of monetary. Conversely, in cost utility 
analysis the measurement of outcome is not done on shared natural units. Health benefits in 
cost utility analysis are analysed on the basis of patient survival i.e. utility which is not 
comprised of a particular disease. Thus, cost utility analysis has an ability of comparing the 
worth of interventions in two or more medical areas. The utility measurement is a difficult 
task as the outcome measure such as QALY (quality adjusted life year) cannot be defined 
precisely that ultimately fails to transfer to other evaluation. Different viewpoints and 
priorities in different ailments can be gained by measuring quality of life. Specific cautions 
should be taken to empower league of QALY to provide evaluations of the value of money 
derived from the number of therapies [65]. These tables values cannot be compared as they 
are obtained from different approaches used at unscheduled time on variety of people [66]. 
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II. Materials and Methods 
7. Modelling in R and Shiny 
Once R and RStudio were learnt, in order to practise the learnings and accomplish the aim of 
the study, modelling was commenced with simple plotting and calculations using some basic 
code of R. Later Shiny was explored and an application in Shiny was built by moving step by 
step in the creation of a model. Following are the steps that were used to enhance the learning 
in this study. 
7.1. Basic code for plotting and PK parameters calculations  
Based on data from Olmesartan concentration-time profiles obtained from two drug products 
in a bioequivalence study data (in house data), R code (See Attachment 1) was performed to 
plot dataas concentration vs time, log of concentration vs time and average concentrations vs 
time.. BLQ (Below Quantification Limit) was assumed as zero concentration value. 
Additionally, pharmacokinetic parameters Cmax, tmax and AUC0-t (by trapezoidal method) 
were calculated for all subjects and both formulations. Attachment 2 comprise of all the code 
used step by step for the successful plotting and calculations. Attachment 3 has the resulted 
plots of each formulation with the variations in the size and colour of the plots. The results for 
pharmacokinetic parameters required can be achieved from Attachment 4. 
7.2. Model with Ordinary Differential Equation (ODE) in Shiny 
After the successful attempt of dealing with the simple model in RStudio, Shiny was used to 
create simple models following by complexity in each new model built, in order to reach 
towards the targeted model.  
At the beginning, model built created an application in the browser with the simple user 
interface that gave it an appearance (without any widget, slider, checkboxes, etc.). Later to 
increase the complexity, an ordinary differential equation (dA = -KE*A) was added in the 
model with fixed effects parameters (THETA) where the rate of elimination (KE) was 
estimated to be 0.09, and Volume of distribution equals to 25 (See Attachment 5). The R 
scripts used to create this model are available in Attachment 5. 
7.3. Model with ETA in Shiny 
Next, the model with the inclusion of ETA was built where ETA is represented by random 
effects as a quantity and demonstrates the difference in values of population and individual 
parameter. It is expected to be distributed normally or log-normally in evaluated population 
with zero mean and precise by its SD (Standard Deviation). In this model, number of subject 
(n) used was 10 and ETA for population volume (POPV) and population rate of elimination 
(POPKE) was used with the same ordinary differential equation (dA = -KE*A) (See 
Attachment 6). 
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7.4. Model with Confidence Interval (CI) 
The previous model was then modified by the addition of confidence interval (CI) values that 
is used by statisticians to define the interval estimate in which true values of population 
parameters might exist. It appeared in a plot as a shaded region with the given colour (red), 
according to the defined CI limits. The percentiles used for the CI were 2.5 % and 97.5 % 
(Attachment 7). The concentration plotted in the model with CI was the median concentration 
of the population, where median concentration can be replaced by mean concentration that is 
shown in next model. 
7.5. Model with Slide bars 
In this model, slide bars were further included with an addition of code in both R scripts (ui.R 
and server.R). The slide bars added were for the dose administered, rate of elimination (KE), 
volume of distribution (V), standard deviation of V, and standard deviation of KE 
(Attachment 8). The aim of the added slide bars was to analyse the change in the plot with the 
change of slides when moved from one value to another. This reveals how these variables can 
affect the plotting curve or the concentration of drug. The concentration plotted in the model 
with CI was the mean concentration of the population. 
7.6. Modelling with the two compartmental models 
Further, the model was then updated to work with two compartmental models (Attachment 9), 
where concentrations from each compartment were plotted with varied colours. CONC1 was 
referred to central compartment while CONC2 was assumed for peripheral compartment. The 
volume of distribution in each compartment was defined by V1 and V2 in first and second 
compartment respectively. Dose of 300mg was administered here with a frequency of 1 that 
means one per day. This model was built without Shiny in order to confirm the appropriate 
working of the each code before integrating it into Shiny. Three ordinary differential 
equations were used (Attachment 9), which are as follows: 
dA[1] = -Ka*A[1] 
dA[2] = Ka * A[1] - (K10 + K12) * A[2] + K21 * A[3] 
dA[3] =  K12 * A[2] -  K21 * A[3] 
 
In these equations, A[1] predicts the amount of dose at the time of administration; A[2] 
demonstrates the amount of drug in central (first) compartment while A[3] depicts the amount 
of drug in peripheral (second) compartment. CONC 1 was calculated by dividing A[2] by V1, 
similarly CONC2 was calculated by dividing A[3] by V2. Consequently two data frames were 
created along with the calculations of their variables and concentrations that were later 
merged together with time to make concentrations vs time plot at the same chart for each 
concentration. Here the median of each concentration was used against time to make the plot. 
Moreover, the model was the improved by adding confidence interval for each of the 
concentrations in the plot (See Attachment 10).  
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8. Final modelling 
The aim of these entire model building was to get enough skilled for the building of the final 
model that is related to the population pharmacokinetic analysis of Glecaprevir and 
Pibrentasvir drugs. Mavyret
®
 is the branded name of the fixed dose combination of these two 
drugs. Both Glecaprevir and Pibrentasvir are viral protein inhibitors: Glecaprevir (100mg) 
inhibits serine protease NS3/4A while Pibrentasvir (40mg) inhibits zinc binding hydrophilic 
phosphoprotein NS5A [67]. These proteins are significant for the viral RNA replication in 
hepatitis C, and by inhibiting these proteins this replication can be stopped [68]. 
In August 2017, Mavyret
®
 was approved by the Food and Drug Administration (FDA) [69] 
for the treatment of hepatitis C virus (HCV) genotypes 1-6 with mild or no cirrhosis and with 
mild to severe kidney disease [70]. For the approval of Mavyret
®
, a population PK analysis 
was performed [71] or Glecaprevir and Pibrentasvir based on data from a population of 
patients with HCV (as monotherapy or combined therapy) , in order to classify the factors that 
can affect variability in the pharmacokinetics of Glecaprevir and Pibrentasvir..  
8.1. Glecaprevir (GLE) modelling 
A model was initially built only one drug (Glecaprevir), based on details described in the 
report from FDA for Mavyret
®
. Glecaprevir modelling in population pharmacokinetic 
analysis used data from subjects who received Glecaprevir with measurable concentrations. 
Quantity of dose administered in each subject was 300mg once a day. The popPK model was 
created with Shiny (Attachment 11) in order to observe the difference in the results with the 
changing of the covariates included as the selection boxes and checkboxes. This model had 
pretty much error and mistakes that needed to be altered to improve the appearance and 
working of the model such as the selection boxes were required to be replaced by the sliders 
or the check boxes for the ease in selecting the value. Later, with the modification of each 
model, many changing were made. The main purpose of this model was to deal with the 
values and equations required for the population pharmacokinetic analysis of Glecaprevir. As 
this model was not the final one, the number of subjects to simulate PK profiles was only 10. 
The values used for the analysis were taken from the table of parameter estimates (Table 2) 
[71]. The structural model was a two-compartment open model with a volume of distribution 
for the central compartment (V2/F) and for the peripheral compartment (V3/F), clearance 
(CL/F), rate of absorption (KA) and inter-compartmental clearance (Q/F). The two-
compartmental pharmacokinetic model included also a first order absorption and elimination 
processes (Table 2) [71]. PopPK model showed a high inter individual variability (IIV) in 
bioavailability parameter (230%).  
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Table 2 : Parameter estimates for the final Glecaprevir model [71]. IIV = inter-individual variability, 
SEE = Standard Error of Estimate, % RSE = (Relative Standard Error),  
%𝐑𝐒𝐄 =
𝑺𝑬𝑬
𝑷𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒆𝒔𝒕𝒊𝒎𝒂𝒕𝒆
∗ 𝟏𝟎𝟎 
8.2. Pibrentasvir (PIB) modelling 
Based on the popPK analysis described in the report form the FDA for Mavyret
®
, another 
drug model  was built for Pibrentasvir with the intention of updating the successful modelling 
of each drug in a combined model. The dose administered in each subject was 120mg on the 
same regimen (once a day) as Glecaprevir. Like Glecaprevir model, the model for 
Pibrentasvir was also built in Shiny to observe the changings in results with the change of 
values of covariates (see Attachment 12) that are provided as a selection boxes for age, renal 
function and gender, while for Asian race and cirrhosis, checkboxes are available. Based on 
Shiny code, it is possible to observe any change in the plot by just changing the selected 
values. The number of subjects used to simulate PK profiles in this model was also 10, that 
was later increased to 1000 when a combined model was built. In Table 3 [71] are presented 
the parameter estimates values used in the model,  
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Table 3: Parameter estimates for the final Pibrentasvir model [71]. IIV = inter-individual 
variability, SEE = Standard Error of Estimate, % RSE = (Relative Standard Error),  
%𝐑𝐒𝐄 =
𝑺𝑬𝑬
𝑷𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒆𝒔𝒕𝒊𝒎𝒂𝒕𝒆
∗ 𝟏𝟎𝟎 
8.3. GLE and PIB modelling (with Shiny) 
Estimate values for model parameters and IIV presented in Table 2 (Glecaprevir) and Table 3 
(Pibrentasvir) were used in an updated model where final PK profile simulations had to be 
done. The server script in Shiny controls the user input to show output in user interface. As 
shown in this model (Attachment 11 and 12), the server.R script consist of two parts where 
one part deals with the processing and calling reactive inputs and giving output inside the 
shiny server, whereas the other part include the non-reactive expressions and functions that 
are independent of widget inputs. The principle of dividing functions and expressions in both 
parts is to separate the functions or expressions that are required to evaluate every time when 
input changes with the ones that do not need re-evaluation again and again. Before 
introducing Shiny server, all the libraries of the required packages are loaded, including the 
time sequence, function for differential equation and ggplot2 themes. These functions are just 
executed when the application is started or it is re-opened in the Web browser. These 
commands do not react with the change of input; however they are placed in a nonreactive 
area i.e. outside of ShinyServer. The functions within the ShinyServer are re-executed every 
time with the widget change, thus reactive expressions and render* functions are placed inside 
the shinyServer as they depend on widget input. The reactive expressions used in this 
application are as follows: 
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shinyServer(function(input, output) { 
sim.data <- reactive ({ 
    SEX <- input$SEX 
    C <- input$C 
    AR <- input$AR  
    AGE <- input$AGE 
    O <- input$O 
    RI <- input$RI 
 
In this code, SEX, C (cirrhosis), AR (Asian race), O (Opioids), Age and RI (Renal 
Impairment) are the series of input$X function that are used to make a data frame called 
sim.data.df (at the end) that includes the calculations of time and concentrations for further 
use in plots or for calculating the pharmacokinetic parameters. This data frame also changes 
according to the change in widget inputs. Changing the dosing regimen or covariate values 
allow the user to see rapid results simultaneously. The incorporation of variety of widgets 
offers to simulate different situations without changing the model code, R processing code for 
output or input dataset. 
The differential equations are represented by the deSolve [72] package used in the server.R 
script (Attachment 13). The application use R language to simulate the population by 
sampling their parameters randomly so that each patient owns a parameter set. Here, the 
differential equation solver uses the input of differential equations and parameter sets to 
obtain the data of concentration-time for both drugs (Glecaprevir and Pibrentasvir) from 0 to 
90 days with the difference of 0.02 days. In the subsequent data frame such as “sim.data.df” 
(Attachment 13), the mean, upper percentile and lower percentiles for Glecaprevir and 
Pibrentasvir concentrations are calculated. Consequently, the plots displayed in the user-
interface show two solid lines, blue and red for Glecaprevir and Pibrentasvir mean 
concentrations respectively, whereas the shaded ribbon with the similar colours represent the 
upper and lower percentiles of each of their concentrations. 
In Attachment 13, R generates random numbers that are simulated by number of random 
effect parameters (n) from normal distribution for every parameter, where mean is considered 
as zero and standard deviation is described according to the values placed in Table 2 and 
Table 3 for each drug. Each random effect parameter is corresponded with other parameter 
that is in the similar place of n-value log sequence, in which the values of population 
parameter are distributed log-normally and, for the corresponding parameter, the calculation 
uses the value of population and the value of each patient for the random effect. The 
population size here is dependent on the input n in this model that should be written in 
reactive expression in ShinyServer as the code to define parameter values is reactive. The 
number of population (n) was increased in this model to 1000 and the prediction of time-
course was improved.  
Several pharmacokinetic systems are very difficult to be represented as an analytical solution, 
thus we have used three as follows differential equations: 
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  dA[1] = -Ka*A[1] 
  dA[2] = Ka * A[1] - (Cl/V1 + Q/V1) * A[2] + Q/V2 * A[3] 
  dA[3] =  Q/V1 * A[2] -  Q/V2 * A[3] 
 
Where dA[1], dA[2] and dA[3] define the differential equations by demonstrating the rate of 
change in the amount of both drugs for the two compartments, where Cl/V1 is the rate of 
elimination (K10), Q/V1 represent the rate of transfer from central compartment to peripheral 
compartment (K12) and Q/V2 demonstrates the rate of transfer from peripheral compartment 
to central compartment i.e. K21. 
The Isoda function (Attachment 13) is from deSolve [72] package that is used to analyse the 
amount of glecaprevir and pibrentasvir in each compartment with the time period of 0 to 90 
days and interval of 0.02 days. Several arguments are taken by Isoda function.  
sim.data.df.gle <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata))  
 
sim.data.df.pib <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata)) 
 
In these code, A_0 describe the first values of the differential system, TIME defines the time 
to calculate the value of A in each compartment, DES function is a function of R that define 
the differential equations in the model, THETAlist describes the parameter values list that 
state the DES function and events = list(data=DOSEdata) define the data used for dosing 
regimen and the frequency of dose intake. Isoda can calculate the amount of drug at every 
defined time with the incorporation of differential equation system. Only one set of parameter 
values can be used by Isoda such as one value of every rate constant (Cl, V1, V2, Q and Ka) 
(Attachment 13). This model can evaluate the effects on population of different values of 
covariates and dosing regimens and can ultimately predict intervals and mean concentrations. 
In parameter data frame, parameter sets are arranged in one row to deliver an input to R 
function, such as “simulate.conc” function consisting of Isoda and input parameters and initial 
condition expressions. The “simulate.conc” function transfers through each row of parameter 
sets or data frame in order to calculate the amount of Glecaprevir and Pibrentasvir at the 
specified time. This process is done by using the “ddply” function from the “plyr” [73] 
package.  
The automatic updating in the model of Shiny might require long time to update the plot upon 
the input change. Thus, the compiler [53] package in R (as shown in Attachment 13) can 
increase the speed of the process. Unlike R, compiled function save the code in an executable 
file of machine instructions while R save the code as text files that slow the speed at runtime. 
By applying a byte code compiler, benefits are provided by compiled code in R with the 
compiler package and “cmpfun” function (Attachment 13). This Attachment has the functions 
that define the differential equations (DES) in the model and simulate.conc is called to solve 
the system according to the number of individuals (n) defined with every change in widget as 
they are written for sim.data in the reactive expression. In the compiler package, the “cmpfun” 
function can be used to compile the functions as stated below (Attachment 13). 
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simulate.conc.cmpf <- cmpfun(simulate.conc) 
As this model was built in shiny application, it can be seen in the user-interface or the 
application display that different input functions are implicated for different selections such as 
“numericInput” is used to select the age range of the individuals, for the renal function and 
gender selection the function “selectInput” is used while to mention the presence of opioids, 
Asian race and cirrhosis “checkbxInput” functions are used. For the separation of the plots of 
both drugs and their concentrations-time profiles in both compartments, tabs are created in 
ui.R of Attachment 13, where three tabs are made with “tabPanel” function named as 
Glecaprevir (displays the plot of mean concentrations of Glecaprevir in both compartments 
against time) and named as Pibrentasvir (displays the plot of mean concentrations of 
Pibrentasvir in both compartments against time), , and also named Pibrentasvir & Glecaprevir 
tab that shows the plot of the mean concentrations of both drugs in first compartment against 
time. However, due to some complications faced in this model, another models were built to 
overcome the problems and for the accuracy of the results. Below are the equations for 
clearance used in Attachment 13: 
Glecaprevir: Cl <- 1150* exp(-0.330*input$AGE)* exp(1.03*MRI)* exp(0.706*MSRI)* 
exp(0.530*ESI)* exp(0.814*SEX_C)* exp(0.763*input$C)* exp(0.900*input$O)  
 
Pibrentasvir: Cl <- 6340* exp(0.778*SEX_C)* exp(0.988*MRI)* exp(0.918*MSRI)* 
exp(0.646*ESI)* exp(0.810*input$AR)* exp(-0.148*input$AGE)* exp(0.912*input$C) 
Where the clearance resulted in “zero” with the zero value of any of the covariates, thus each 
of these covariates was dealt separately in their individual models. MRI = Mild Renal 
Impairment, MSRI = Moderate + Severe renal Impairment, ESI = End Stage Impairment, AR 
= Asian Race, SEX_C = Gender, and C = Cirrhosis. 
8.4. GLE and PIB modelling (without Shiny) 
Further models were created without Shiny to deal with the variabilities separately. The total 
number of models built was seven, each of them having different covariates and one without 
any covariate. In these models, the age was calculated with the help of FDA submission 
report [71] for maviret and results of clinical trials practised in that report.  
Phase 2 studies Age  [Units: Years] 
Mean (Standard Deviation) 
M13-595                  54.1  (9.17)  
M14-867             54.1  (9.98)                                 
M14-868                      < 65 years       =   616 
>= 65 years     =   75 
M15-410                          55.9  (7.88)  
Table 4: Average ages of Phase 2 clinical studies made in FDA submission report for Mavyret
®
 
[71], accessed in clinical trial website [74]. 
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The average ages of all the clinical studies for both drugs were accessed from the clinical 
trials website [74] by entering the clinical trial numbers as mentioned in FDA submission 
report for Mavyret
®
 [71], where four Phase 2 studies were made (Studies M13-595, M14-867, 
M14-868 and M15-410) (Table 4) and six Phase 3 studies were made (Studies M13-583, 
M13-590, M13-594, M14-172, M15-462, and M15-464) (Table 5) [71]. The table of 
calculations of the mean age from these studies result and the formula used can be seen in 
(Attachment 21). 
Phase 3 studies                       Age  [Units: Years] 
Mean (Standard Deviation) 
M13-583                52.66  (10.95)   
M13-590                50.93  (11.77) 
M13-594                46.61  (11.32)  
M14-172                 60.12  (10.43)   
M15-462              57.52  (11.14)   
M15-464              57.04  (12.53) 
Table 5: Average ages of Phase 3 clinical studies made in FDA submission report for Mavyret
®
 
[71], accessed in clinical trial website [74]. 
 
 Model without any covariate 
Model constructed without any covariate is accessible in Attachment 14, in which none of the 
covariates is included and the population with (n <- 1000) is simulated by setting the values of 
each covariate equals to “0” in order to predict their absence in the individuals. Here the 
clearance (CL) for both drugs is written alone such as (GLE: Cl <- 1150) and (PIB: Cl <- 
6340). 
 Model with mild renal impairment 
Model built with mild renal impairment is presented in Attachment 15, where the input for 
mild renal impairment (as MRI in attachment 15) is set equal to “1” to show the existence of 
the covariate, while the rest of them are still equal to “0”. The equation for clearance (Cl) 
possess the values of mild renal impairment according to the Table 2 and Table 3 for each 
drug which ultimately multiplies the value with “1” and the resulting clearance can be 
achieved that will affect the concentration-time profiles of the drugs. Clearance in the model 
is stated as Cl <- 6340*(0.988*MRI) for pibrentasvir, and Cl <- 1150*(1.03*MRI) for 
glecaprevir.  
 Model with mild renal impairment and cirrhosis 
Model created with mild renal impairment and cirrhosis is obtainable in Attachment 16, in 
which the input for both mild renal impairment (MRI) and cirrhosis (C) (in Attachment 16) 
are set to “1” for counting their presence in the model with the other inputs equal to “0”. Here 
the equation for clearance (Cl) retains the values for mild renal impairment and cirrhosis as 
illustrated in Table 2 and Table 3 for glecaprevir and pibrentasvir respectively. In the model 
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the clearance is stated as Cl <- 1150*(1.03*MRI)*(0.763*C) for glecaprevir, and Cl <- 
6340*(0.988*MRI)*(0.912*C) for pibrentasvir. 
 Model with moderate + severe renal impairment 
Model produced with moderate plus severe renal impairment is accessible in Attachment 17, 
in which the input value of moderate + severe renal impairment (as MSRI in model) is set to 
“1” and rest equal to “0” to calculate the clearance for each drug that has the values of 
moderate + severe renal impairment in its equations. The equations in the model are; GLE: Cl 
<- 1150*(0.706*MSRI) and PIB: Cl <- 6340*(0.918*MSRI). 
 Model with moderate + severe renal impairment and cirrhosis 
Model built with moderate plus severe renal impairment and cirrhosis is available in 
Attachment 18, where the input values for moderate + severe renal impairment (as MSRI) and 
cirrhosis (as C) is equal to “1” to predict the existence of both at the same time, whereas other 
covariates are neglected by considering them as “0”. The equation for clearance for both 
drugs consist the values of cirrhosis and moderate + severe renal impairment as shown in 
Table 2 and Table 3 and are written in the model as Cl <- 1150*(0.706*MSRI)*(0.763*C) for 
glecaprevir and as Cl <- 6340*(0.918*MSRI)*(0.912*C) for pibrentasvir.  
 Model with end stage impairment 
Model constructed with end stage impairment is presented in Attachment 19, in which the 
input for end stage impairment (as ESI in model) is set equal to “1” by considering other 
inputs absent and equal to “0”. As the clearance will be affected by the end stage impairment, 
its value will be included in the equation of each drug such as GLE: Cl <- 1150*(0.763*C) 
and PIB: Cl <- 6340*(0.912*C) (As shown in the Attachment 19). 
 Model with end stage impairment and cirrhosis 
Model created with end stage renal impairment and cirrhosis is accessible in Attachment 20. 
In this model the input for both end stage impairment and cirrhosis is considered as “1” as 
both of them is assumed to be present in the population. Similar to other models, the clearance 
for each drug will also be affected here. Therefore, the values for end stage impairment and 
cirrhosis as stated in Table 2 and Table 3 are included in the clearance equation in the model 
such as GLE: Cl <- 1150*(0.530*ESI)*(0.763*C) and PIB: Cl <- 
6340*(0.646*ESI)*(0.912*C). 
9. Pharmacokinetics parameters calculations 
At the end of each of the above Glecaprevir and Pibrentasvir model (Attachment 14-20), a 
calculation is done to evaluate the AUC (area under the curve) and Cmax (maximum 
concentration) of each plot. First, the data frames were created for each of the drug 
comprising the subjects and AUC with an interval of (85-86) day and named as Auc.gle and 
Auc.pib, later these two data frames (for both drugs) were merged together against subjects 
and a new data frame was formed (Auc.data.df).  
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Similarly, two more data frames were created in order to calculate the Cmax of each drug and 
the data frames created were cmax.gle (for glecaprevir) and cmax.pib (for pibrentasvir). Then 
both of these data frames were merged together in one data frame with the name of 
cmax.data.df in which the Cmax of both drugs were calculated against subjects. 
At the end, both of the merged data frames of AUC (Auc.data.df) and Cmax (cmax.data.df) 
were merged in one more new data frame with the subjects that were named as AUC.CMAX 
on the models. This final data frame (AUC.CMAX) was now comprised of all the required 
information in one data frame such as AUC and Cmax for both drugs that was later used to 
make further pharmacokinetic calculations. 
Lastly, the required calculations were arithmetic mean, geometric mean, standard deviation 
and coefficient of variation of AUC and Cmax for both drugs. Thus, a matrix was created 
with 4 numbers of columns and 4 numbers of rows to calculate each of the required 
calculation and arrange them in a table. The name given to the matrix in the models was 
(summary_table), in which the rows were named as Arithmetic mean, Geometric mean, 
standard deviation and coefficient of variation while the columns were named as 
("GLE.CMAX", "PIB.CMAX", "GLE.AUC", "PIB.AUC"). The arithmetic mean was 
calculated with the “mean” function in R, geometric mean was calculated with 
“geometric.mean" function, stanadard deviation with “sd” and coefficient of variation by 
dividing standard deviation by Arithmetic mean. The resultant table was then saved as a csv 
file in excel file by the command “write.csv(summary_table, "Calculations.csv")”.  
III. Results and Conclusions 
10. Modelling in R and Shiny 
The results and plots obtained at the end of each model built in R and Shiny application are 
shown below. The order of the model results is maintained according to the models defined in 
materials and methods. 
10.1. Basic code for plotting and PK parameters caculations 
Proper log-linear curves were obtained for each of the products where the observed 
continuous points in the plot signify the data incorporated by a bi-exponential function which 
can be evaluated by mono-exponential function. Figure 4 shows an example of the plots 
obtained from the simple concentration-time profiles, whereas rest plots for both test and 
reference products for each subject can be seen in Attachment 3. Similarly, Figure 5 shows a 
perfect curve for log concentration vs time plot for each formulation.  
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Figure 4: Average of plasma concentrations vs time plot for two drug products (Test and 
Reference) after oral administration. (Attachment 3) 
 
Figure 5: Average of log of concentrations vs time plot for two drug products (Test and 
Reference) after oral administration. (Attachment 3) 
10.2. Model with Ordinary Differential Equation (ODE) in Shiny 
 
Figure 6: Concentration-time graph plotted in Shiny application after intravenous 
administration with the addition of Differential equations. (Attachment 5) 
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The plot shows a perfect curve of concentration-time where the bioavailability (F) of the drug 
is seen 100%.  
10.3. Model with ETA in Shiny 
The values of ETA in this model were added to see the difference in the plot and it resulted in 
a proper curve of concentration-time profile. 
 
Figure 7: Concentration-time graph plotted in Shiny application after intravenous 
administration with the addition of ETA (random effects in the model). (Attachment 6) 
10.4. Model with Confidence Interval (CI) 
This model was built in Shiny application to deal with the values of confidence interval that 
worked successfully. The shaded ribbons of red colour are showing the area of the confidence 
interval where the true values of concentration is potentially present.  
 
Figure 8: Simple concentration-time graph in Shiny with the calculation of their confidence 
interval (Attachment 7) 
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10.5. Model with Slide bars 
This model was created in Shiny with the modifications in the previous model and with the 
addition of slide bars in the user interface of the application where the sliders help to view the 
instant change in the plot when they are moved from one value to another. The graph shown 
in Figure 9 is updated with the change in slide bars shown in Figure 10.  
 
Figure 9: Concentration-time plot of a model in Shiny where slide bars are added to observe the 
change in graph simultaneously (Attachment 8) 
 
Figure 10: Slide bars in the model created to observe the change in plot upon moving the sliders 
from one value to another (Attachment 8) 
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10.6. Modelling with the two compartmental models (Attachment 9,10) 
 
Figure 11: Model created with two compartmental model where concentrations in both 
compartments are plotted with the confidence interval of the concentration in central 
compartment 
This model was created to practice the plotting of two concentrations at the same time, in the 
same chart. Figure 11 shows the two concentrations of one drug that are in central and 
peripheral compartment, on the other hand the concentration in central compartment also 
show the confidence interval that is displayed as a shaded region in red colour. The successful 
plotting of two concentrations in one chart further enabled the plotting of two drug 
concentrations with their confidence intervals at the same time as illustrated in final 
modelling. 
11. Final modelling 
As all of the above models were created to practice for building the final model for the 
intended drugs (Glecaprevir and Pibrentasvir), further models were initiated that exhibited the 
following results. 
11.1. Glecaprevir (GLE) modelling (Attachment 11) 
One of the modelling drugs (Glecaprevir) to be analysed was used to build a model in the 
initial level of modelling in order to observe it alone and to practice for further combined 
modelling. The model created was in Shiny where the selection boxes and check boxes were 
used to create choosing options for age, renal impairment, gender, opioids and cirrhosis. The 
subsequent plot displayed in the shiny application shows the two concentrations in two 
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compartmental model for Glecaprevir, which show a rise in the initial days but seem to get at 
steady state levels later on Figure 12. 
 
Figure 12: This figure shows the screenshoot of the resultant display of user interface used in the 
building model of Glecaprevir in Shiny (Attachment 11) 
11.2. Pibrentasvir (PIB) modelling (Attachment 12) 
Further, a model was created with the intended modelling drug (Pibrentasvir) where all the 
possibilities were practiced to see the resulting display of Shiny application in the browser 
and the plot of each concentration values of Pibrentasvir in central and peripheral 
compartment. The selection boxes and check boxes are used to change the desired covariate in 
the model and observe the updated plot simultaneously. The resultant graph is displaying the 
rise in concentrations at the initial phase whereas it gets steady state later Figure 13. 
 
Figure 13: This figure shows the screenshoot of the resultant display of user interface used in the 
building model of Pibrentasvir in Shiny (Attachment 12) 
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11.3. GLE and PIB modelling (with Shiny) (Attachment 13) 
After building the individual models of Glecaprevir and Pibrentasvir in Shiny, a combined 
model was created also in Shiny to deal with all the covariates and the drug concentrations in 
one window. Figure 14 demonstrate the view of the final work in the model where three tabs 
were created to observe the concentrations of each drug with the change of the given 
covariates. By changing the tabs, the plot is updated and the concentrations as per drug are 
shown. The first two tabs of Pibrentasvir and Glecaprevir display the two concentrations of 
each one in two compartmental model, whereas the third tab show the concentrations of both 
drugs in the central compartment. All of these concentrations are affected by changing any of 
the covariate. To practice all of the stated information (Attachment 13) can be used. 
 
Figure 14: This figure shows the screenshoot of the resultant display of user interface used in the 
building model of Glecaprevir and Pibrentasvir in Shiny (Attachment 13) 
11.4. GLE and PIB modelling (without Shiny) 
Following models were created without Shiny in order to reach to accurate values by setting 
different covariates at one time in a specific group of population: 
 Model without any covariate (Attachment 14) 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 0.824095 0.038707 0.261131 0.019951 
Geometric Mean 0.822467 0.036797 0.259168 0.019147 
Standard Deviation 0.05187 0.01241 0.032251 0.005804 
Coefficient of variation 0.062941 0.320616 0.123506 0.290919 
Table 6: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when no covariate is used in the model 
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Figure 15: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
red and Glecaprevir in blue in central 
compartment without using any covariate in 
the subjects 
 
Figure 16: The plot in this figure shows the 
mean concentration of Pibrentasvir in 
central compartment without with using 
any covariate in the subjects 
 
Figure 17: The graph in this figure shows 
the mean concentration of Glecaprevir only 
in central compartment without using any 
covariate in the subjects 
 
Figure 18: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
central compartment with the interval of 85-
87 days and without using any covariate in 
the subjects 
 Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals 
 
 
40 
 
 
Figure 19: The graph in this figure shows 
the mean concentrations of Glecaprevir in 
central compartment with the interval of 85-
87 days and without using any covariate in 
the subjects 
 
 
 
 
 
 
 
 
 
 
 Model with mild renal impairment (Attachment 15) 
 
Figure 20: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
red and Glecaprevir in blue in central 
compartment with the group of patients that 
are suffering with mild renal impairment 
 
Figure 21: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment with the group of 
patients that are suffering with mild renal 
impairment 
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Figure 22: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment with the group of 
patients that are suffering with mild renal 
impairment 
 
Figure 23: The graph in this figure shows 
the mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with mild renal impairment 
 
Figure 24: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with mild renal impairment 
 
 
 
 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 0.814563 0.038977 0.255169 0.019799 
Geometric Mean 0.813065 0.036911 0.253392 0.018982 
Standard Deviation 0.049457 0.013318 0.030281 0.005854 
Coefficient of variation 0.060716 0.341684 0.118671 0.295689 
Table 7:  The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment is 
used 
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 Model with mild renal impairment and cirrhosis (Attachment 16) 
 
 
Figure 25: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
red and Glecaprevir in blue in central 
compartment with the group of patients that 
are suffering with mild renal impairment 
and Cirrhosis 
 
Figure 26: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment with the group of 
patients that are suffering with mild renal 
impairment and Cirrhosis 
 
Figure 27: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment with the group of 
patients that are suffering with mild renal 
impairment and Cirrhosis 
 
Figure 28: The graph in this figure shows 
the mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with mild renal impairment 
and Cirrhosis 
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Figure 29: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with mild renal impairment 
and Cirrhosis 
 
 
 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 0.931279 0.042044 0.333353 0.0216 
Geometric Mean 0.929869 0.039949 0.331217 0.020768 
Standard Deviation 0.051246 0.013595 0.037857 0.006111 
Coefficient of variation 0.055028 0.323359 0.113565 0.282894 
Table 8: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment 
and cirrhosis is used 
 Model with moderate + severe renal impairment (Attachment 17) 
 
Figure 30: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
red and Glecaprevir in blue in central 
compartment with the group of patients that 
are suffering with moderate + severe renal 
impairment 
 
Figure 31: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment with the group of 
patients that are suffering with moderate + 
severe renal impairment 
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Figure 32: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment with the group of 
patients that are suffering with moderate + 
severe renal impairment 
 
Figure 33: The graph in this figure shows 
the mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with moderate + severe renal 
impairment 
 
Figure 34: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with moderate + severe renal 
impairment 
 
 
 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 0.978824 0.041447 0.369546 0.021321 
Geometric Mean 0.977349 0.039282 0.367161 0.020451 
Standard Deviation 0.053846 0.013902 0.042226 0.006291 
Coefficient of variation 0.055011 0.335419 0.114264 0.29507 
Table 9:  The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with patients of moderate + severe renal 
impairment is used 
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 Model with moderate + severe renal impairment and cirrhosis 
(Attachment 18) 
 
Figure 35: The graph in this figure shows 
the mean concentrations of  Pibrentasvir in 
red and Glecaprevir in blue in central 
compartment with the group of patients that 
are suffering with moderate + severe renal 
impairment and cirrhosis 
 
Figure 36: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment with the group of 
patients that are suffering with moderate + 
severe renal impairment and cirrhosis 
 
Figure 37: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment with the group of 
patients that are suffering with moderate + 
severe renal impairment and cirrhosis 
 
Figure 38: The graph in this figure shows 
the mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with moderate + severe renal 
impairment and cirrhosis 
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Figure 39: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with moderate + severe renal 
impairment and cirrhosis 
 
 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 1.115564 0.044258 0.484677 0.023477 
Geometric Mean 1.113829 0.041907 0.481451 0.022452 
Standard Deviation 0.062414 0.015033 0.056307 0.007222 
Coefficient of variation 0.055949 0.339669 0.116174 0.30764 
Table 10: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment 
and cirrhosis is used  
 Model with end stage impairment (Attachment 19) 
 
Figure 40: The plot in this figure shows the 
mean concentrations of  Pibrentasvir in red 
and Glecaprevir in blue in central 
compartment with the group of patients that 
are suffering with end stage impairment 
 
Figure 41: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment with the group of 
patients that are suffering with end stage 
impairment 
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Figure 42: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment with the group of 
patients that are suffering with end stage 
impairment 
 
Figure 43: The plot in this figure shows the 
mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with end stage impairment 
 
Figure 44: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with end stage impairment 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 1.127802 0.051868 0.495759 0.03053 
Geometric Mean 1.125976 0.049584 0.492348 0.02933 
Standard Deviation 0.06429 0.016269 0.058372 0.008838 
Coefficient of variation 0.057005 0.313667 0.117742 0.289473 
Table 11: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with patients end stage impairment is used 
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 Model with end stage impairment and cirrhosis (Attachment 20) 
 
Figure 45: The plot in this figure shows the 
mean concentrations of  Pibrentasvir in red 
and Glecaprevir in blue in central 
compartment in the group of patients that 
are suffering with end stage impairment and 
cirrhosis 
 
Figure 46: The graph in this figure shows 
the mean concentrations of Pibrentasvir in 
central compartment in the group of 
patients that are suffering with end stage 
impairment and cirrhosis 
 
 
Figure 47: The graph in this figure shows 
the mean concentrations of  Glecaprevir in 
central compartment in the group of 
patients that are suffering with end stage 
impairment and cirrhosis 
 
Figure 48: The plot in this figure shows the 
mean concentration of Pibrentasvir in 
central compartment with the interval of 85-
87 days and in the group of patients that are 
suffering with end stage impairment and 
cirrhosis 
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Figure 49: The graph in this figure shows 
the mean concentration of Glecaprevir in 
central compartment with the interval of 85-
87 days and with the group of patients that 
are suffering with end stage impairment and 
cirrhosis 
 
 
 
 
 
 
 
 
 
 
 
 GLE.CMAX PIB.CMAX GLE.AUC PIB.AUC 
Arithmetic Mean 1.28864 0.055244 0.647627 0.03342 
Geometric Mean 1.286278 0.052398 0.643145 0.031993 
Standard Deviation 0.078388 0.018702 0.07681 0.010143 
Coefficient of variation 0.06083 0.338529 0.118602 0.303504 
Table 12: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both 
drugs (Glecaprevir and Pibrentasvir) when a model with a patients of end stage impairment and 
cirrhosis is used 
All of the above plots of the models with different covariates define the profiles of each of the 
concentrations almost similarly. As it can be seen that the mean concentrations of both drugs 
in each compartment show similar profiles except for the two covariates, moderate + severe 
renal impairment with cirrhosis (Figure 35) and end stage impairment with cirrhosis (Figure 
45) where the mean concentrations of Glecaprevir show higher profile with more gap in 
between than the mean concentrations of Pibrentasvir. This difference from other might be 
resulted due to higher clearance rate as the group of patients with renal impairment and 
cirrhosis are used in both models. All of the plots (except for the interval of 85-87 days) show 
unusual profiles that are due to the dense number of predictions of 1000 individuals in 90 
days. If we look closely to each of them as shown in interval figures between 85-87 days, they 
show a proper and nice plotting where the interval is selected at the steady state of plots. 
Table 6 to Table 12 show the arithmetic mean, geometric mean, standard deviation and 
coefficient of variation for the PK parameters AUC and Cmax of each drug’s concentrations, 
based on simulation of PK profiles for 1000 subjects. Tables containing individual data for 
AUC and Cmax for each drug, with different covariates, can be accessed from Attachment 22 
to Attachment 28. These tables can also be obtained by running each of the models (in 
Attachments) till the end. 
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IV. Conclusion 
Using R for pharmacometric models require skill and Shiny package of R has allowed the 
access of pharmacometric models up to wide extent such as drug development. In all the 
process of this study and learning, I was able to build models in R successfully for the drugs 
with different complexities. Despite the implementation of the population pharmacokinetics 
models, as described in the FDA submission report for Mavyret
®
 (a fixed dose combination 
drug product containing Glecaprevir/Pibrentasvir, indicated for the treatment of chronic 
hepatitis C virus), no further analysis related to the use of pharmacoeconomic methodologies 
was performed, part due to lack of time and time consuming learning of R basics to R 
modelling. 
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VI. Attachments  
Following is a zipped folder that contains all the attachments mentioned that are accessible 
electronically. However, the codes for 2 attachments (Attachment 13) and Attachment 14) can 
be seen directly in the document to have an idea what codes other attachments contain that 
can be electronically accessed.  
Attachment 13 is related to the R file built in Shiny application of GLE and PIB modelling. 
Following are the code for the Attachment 13 in which two scripts are present (Server.R and 
ui.R). 
Attachment 14 as shown below is related to the R file that was built for GLE and PIB 
modelling without any covariate and without Shiny application. Other final attachments such 
as (Attachment 15-Attachment 20 electronically available) contain similar code to Attachment 
13, the only difference is the code for covariates used in each of them and the change in the 
clearance (CL) equations.  
Attachment 23 is also available in the document but in shown partially as it has 1000 subjects 
and AUC and Cmax is calculated for each of them. This part of the attachment just has only 
100 subjects and their AUC and Cmax for each of the drugs (Glecaprevir and Pibrentasvir) 
where the table presented is the partial result of the model with mild renal impairment. 
Attachments such as (Attachment 22 – Attachment 28) will illustrate similar tables of 
calculations but different results due to the differentiation of the covariates in every model. 
Electronic supplementary material as Attachments.Zip  
 
Attachments.zip
 
 
Attachment 13  
 
 Server.R file  
#Load package libraries 
library(shiny) 
library(deSolve) 
library(ggplot2) 
library(plyr) 
library(compiler) 
 
#Code for functions and variables which are not reactive (not dependent on "input$X") 
#ggplot2 theme 
theme_custom <- theme_set(theme_grey(18)) 
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#Function containing differential equations for amount in each compartment  
DES <- function(T, A, THETA) { 
   
  Cl <- THETA[1] 
  V1 <- THETA[2] 
  V2 <- THETA[3] 
  Q <- THETA[4] 
  Ka <- THETA[5] 
   
  dA <- vector(length = 3)  
   
  dA[1] = -Ka*A[1] 
  dA[2] = Ka * A[1] - (Cl/V1 + Q/V1) * A[2] + Q/V2 * A[3] 
  dA[3] =  Q/V1 * A[2] -  Q/V2 * A[3] 
  list(dA)    
} 
 
#Compile DES function 
DES.cmpf <- cmpfun(DES) 
 
#TIME sequence for concentrations to be calculated 
TIME <- seq(from = 0, to = 90, by = 0.02) 
 
#TIMElast is used in later functions for assigning dose events  
TIMElast <- max(TIME) 
 
#Define user-input dependent functions for output 
shinyServer(function(input, output) { 
   
  #Reactive expression to generate the plot, this is called whenever the input changes 
  sim.data <- reactive({ 
     
    #Collect input from user-widgets 
    SEX <- input$SEX 
    C <- input$C 
    AR <- input$AR  
    AGE <- input$AGE 
    RI <- input$RI 
    O <- input$O 
     
    if (input$RI == 1) { 
      MRI  <- 0 
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      MSRI <- 0 
      ESI <- 0 
    }     
 
    if (input$RI == 2) { 
      MRI  <- 1 
      MSRI <- 0 
      ESI <- 0 
    }     
    if (input$RI == 3) { 
      MRI  <- 0 
      MSRI <- 1 
      ESI <- 0 
    }    
  
    if (input$RI == 4) { 
      MRI  <- 0 
      MSRI <- 0 
      ESI <- 1 
    }  
     
    if (input$SEX == 1) { 
      SEX_C <- 0 
    }    
  
    if (input$SEX == 2) { 
      SEX_C <- 1 
    } 
     
    #Function for calculating median, upper and lower confidence intervals for x 
    #Where x will be concentrations for GLE and PIB 
    sumfuncx <- function(x) { 
      stat1 <-  mean(x) 
      stat2 <-  quantile(x, probs=0.025, names=F)  
      stat3 <-  quantile(x, probs=0.975, names=F) 
      result <- c("mean"=stat1, "low"=stat2, "hi"=stat3) 
      result 
    }     
 
#Equations and values 
    Cl <- 6340* exp(0.778*SEX_C)* exp(0.988*MRI)* exp(0.918*MSRI)* exp(0.646*ESI)*  
    exp(0.810*input$AR)* exp(-0.148*input$AGE)* exp(0.912*input$C) #L/day 
    V1 <- 1380     # (L) (Central Compartment) 
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    V2 <- 2250     #(L) (peripheral compartment) 
    Q <- 1660      #(L/Day) 
    Ka <- 6.13 
    K12 <- Q/V1 
    K21 <- Q/V2 
    K10 <- Cl/V 
    #Simulate random  
    n <- 10 
    par.data <- seq(from = 1, to = n, by = 1) 
    par.data <- data.frame(par.data) 
    names(par.data) <- "ID"    
  
    #Define population values 
    POPCl <- Cl 
    POPV1 <- V1  
    POPV2 <- V2 
    POPQ <- Q 
    POPKa <- Ka   
   
    #Define population parameter variability 
    ETACl <- rnorm(n, mean = 0, sd = 0.289) 
    ETAV1<- rnorm(n, mean = 0, sd = 0.578) 
    ETAV2 <- rnorm(n, mean = 0, sd = 0) 
    ETAQ <- rnorm(n, mean = 0, sd = 0) 
    ETAKa <- rnorm(n, mean = 0, sd = 0) 
     
    #Simulate individual values  
    par.data$Cl <- POPCl*exp(ETACl) 
    par.data$V1 <- POPV1*exp(ETAV1)  
    par.data$V2 <- POPV2*exp(ETAV2) 
    par.data$Q <- POPQ*exp(ETAQ) 
    par.data$Ka <- POPKa*exp(ETAKa) 
 
    #Input doses specific to dosing frequency 
    DOSE <- 120  
    freq <- 1  
    ndoses <- TIMElast/freq + 1 
     
    DOSEdata <- data.frame(var    = rep(1, times = ndoses), 
                           time   = seq(0,TIMElast,freq), 
                           value  = rep(DOSE, times = ndoses), 
                           method = rep("add", times = ndoses)) 
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    simulate.conc <- function(par.data) {  
       
      #Parameter vector 
      THETAlist <- c("Cl"= par.data$Cl, 
                     "V1"= par.data$V1, 
                     "V2"= par.data$V2, 
                     "Q"= par.data$Q, 
                     "Ka"= par.data$Ka)  
 
      #Set initial conditions in each compartment 
      A_0 <- c(A1 = 0, A2 = 0, A3 = 0) 
       
      #Run differential equation solver (deSolve package)  
      sim.data.df.pib <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata))   
    } 
       
      #Compile simulate.conc function for pib 
      simulate.conc.cmpf <- cmpfun(simulate.conc) 
      sim.data.df.pib <- ddply(par.data, .(ID, Cl, V1, V2, Q, Ka), simulate.conc.cmpf) 
      
      #GLE model 
       
      Cl <- 1150* exp(-0.330*input$AGE)* exp(1.03*MRI)* exp(0.706*MSRI)*  
      exp(0.530*ESI)* exp(0.814*SEX_C)* exp(0.763*input$C)* exp(0.900*input$O) #L/day 
      V1 <- 130      # (L) (Central Compartment) 
      V2 <- 39.6     #(L) ()perpheral compartment) 
      Q <- 68        #(L/Day) 
      K12 <- Q/V1 
      K21 <- Q/V2 
      K10 <- Cl/V1 
      Ka <- 8.63    #(1/day) 
       
      #Simulate random  
      par.data <- seq(from = 1, to = n, by = 1) 
      par.data <- data.frame(par.data) 
      names(par.data) <- "ID" 
       
      #Define population values 
      POPCl <- Cl 
      POPV1 <- V1  
      POPV2 <- V2 
      POPQ <- Q 
      POPKa <- Ka 
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      #Define population parameter variability 
      ETACl <- rnorm(n, mean = 0, sd = 0.118) 
      ETAV1<- rnorm(n, mean = 0, sd = 0) 
      ETAV2 <- rnorm(n, mean = 0, sd = 0) 
      ETAQ <- rnorm(n, mean = 0, sd = 0) 
      ETAKa <- rnorm(n, mean = 0, sd = 0) 
       
      #Simulate individual values  
      par.data$Cl <- POPCl*exp(ETACl) 
      par.data$V1 <- POPV1*exp(ETAV1)  
      par.data$V2 <- POPV2*exp(ETAV2) 
      par.data$Q <- POPQ*exp(ETAQ) 
      par.data$Ka <- POPKa*exp(ETAKa) 
 
      #Input doses specific to dosing frequency 
      DOSE <- 300  
      freq <- 1 #per day 
      ndoses <- TIMElast/freq + 1 
       
      DOSEdata <- data.frame(var    = rep(1, times = ndoses), 
                             time   = seq(0,TIMElast,freq), 
                             value  = rep(DOSE, times = ndoses), 
                             method = rep("add", times = ndoses)) 
 
      simulate.conc <- function(par.data) {  
         
        #Parameter vector 
        THETAlist <- c("Cl"= par.data$Cl, 
                       "V1"= par.data$V1, 
                       "V2"= par.data$V2, 
                       "Q"= par.data$Q, 
                       "Ka"= par.data$Ka)  
         
        #Set initial conditions in each compartment 
        A_0 <- c(A1 = 0, A2 = 0, A3 = 0) 
        sim.data.df.gle <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata))  
      }  
       
      #Compile simulate.conc function  for gle 
      simulate.conc.cmpf <- cmpfun(simulate.conc) 
      sim.data.df.gle <- ddply(par.data, .(ID, Cl, V1, V2, Q, Ka), simulate.conc.cmpf) 
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      #Process the simulated output  
      sim.data.df.pib <- as.data.frame(sim.data.df.pib) 
      sim.data.df.pib$CONC1 <- sim.data.df.pib$A2/sim.data.df.pib$V1 
      sim.data.df.pib$CONC2 <- sim.data.df.pib$A3/sim.data.df.pib$V2 
      sim.data.df.pib$CONC3 <- sim.data.df.gle$A2/sim.data.df.gle$V1 
      sim.data.df.pib$CONC4 <- sim.data.df.gle$A3/sim.data.df.gle$V2 
      sim.data.df.pib$DAYS <- sim.data.df.pib$time/24 
      sim.data.df.pib <- as.data.frame(sim.data.df.pib) 
       
      #Concentrations in Central compartment for GLE and PIB 
      statsCONC1 <- ddply(sim.data.df.pib, .(TIME), function(sim.data.df.pib) 
sumfuncx(sim.data.df.pib$CONC1)) 
      names(statsCONC1)[c(2,3,4)] <- c("Pmean","Plow","Phi") 
      statsCONC3 <- ddply(sim.data.df.pib, .(TIME), function(sim.data.df.pib) 
sumfuncx(sim.data.df.pib$CONC3))  
      names(statsCONC3)[c(2,3,4)] <- c("Gmean", "Glow", "Ghi") 
       
#Concentrations in Peripheral compartment for GLE and PIB 
      statsCONC2 <- ddply(sim.data.df.pib, .(TIME), function(sim.data.df.pib) 
sumfuncx(sim.data.df.pib$CONC2)) 
      names(statsCONC2)[c(2,3,4)] <- c("P2mean","P2low","P2hi") 
      statsCONC4 <- ddply(sim.data.df.pib, .(TIME), function(sim.data.df.pib.) 
sumfuncx(sim.data.df.pib$CONC4))  
      names(statsCONC4)[c(2,3,4)] <- c("G2mean", "G2low", "G2hi") 
       
      #Combine both datasets 
      sim.data.df.pib <- merge(statsCONC1,statsCONC3,by=c("TIME"),all=T) 
      sim.data.df.pib <- merge(sim.data.df.pib,statsCONC2,by=c("TIME"),all=T) 
      sim.data.df.pib <- merge(sim.data.df.pib,statsCONC4,by=c("TIME"),all=T) 
       
    }) #Brackets closing "reactive" expression 
 
  #Generate a plot of the data 
  #Also uses the inputs to build the plot (ggplot2 package) 
 output$plotCONC1 <- renderPlot({ 
     
    plotobj <- ggplot(sim.data()) +  
      geom_line(aes(x = TIME, y = Pmean), colour = "red", size = 1) +  
      geom_line(aes(x = TIME, y = P2mean), colour = "blue", size = 1) + 
      geom_ribbon(aes(x = TIME, ymin = Plow, ymax = Phi), fill = "red", alpha = 0.3) + 
      geom_ribbon(aes(x = TIME, ymin = P2low, ymax = P2hi), fill = "blue", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)") 
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    print(plotobj)    
  }) 
     output$plotCONC3 <- renderPlot({ 
       
      plotobj <- ggplot(sim.data()) +  
        geom_line(aes(x = TIME, y = Gmean), colour = "blue", size = 1) +  
        geom_line(aes(x = TIME, y = G2mean), colour = "blue", size = 1) + 
        geom_ribbon(aes(x = TIME, ymin = Glow, ymax = Ghi), fill = "blue", alpha = 0.3) + 
        geom_ribbon(aes(x = TIME, ymin = G2low, ymax = G2hi), fill = "blue", alpha = 0.3) + 
        scale_y_continuous("Concentration (mg/L) \n") +  
        scale_x_continuous("\nTime (day)") 
      print(plotobj)  
    }) 
  
    output$plotCONC13 <- renderPlot({ 
       
      plotobj <- ggplot(sim.data()) +  
        geom_line(aes(x = TIME, y = Pmean), colour = "red", size = 1) +  
        geom_line(aes(x = TIME, y = Gmean), colour = "blue", size = 1) + 
        geom_ribbon(aes(x = TIME, ymin = Plow, ymax = Phi), fill = "red", alpha = 0.3) + 
        geom_ribbon(aes(x = TIME, ymin = Glow, ymax = Ghi), fill = "blue", alpha = 0.3) + 
        scale_y_continuous("Concentration (mg/L) \n") +  
        scale_x_continuous("\nTime (day)") 
      print(plotobj) 
       
    }) #Brackets closing "renderPlot" function 
  }) #Brackets closing "shinyServer" 
 
 
 ui.R file 
fixedPage( 
  #Logo and Application Title 
  fixedRow( 
    column(10, 
           h2("Mavyret Glecaprevir/Pibrentasvir Model", align = "center"), offset = 1)  
  ), #Brackets closing "fixedRow" 
     
    hr(), #Add a break with a horizontal line 
     
    #Sidebar Panel with Widgets 
 sidebarLayout( 
              sidebarPanel( 
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              #Heading 
              h4("Patient Information"), 
     
    #Select values for rate constant 
    fluidPage(   
       
      numericInput("AGE", 
                   "Age (Years):", 
                   min = 20, 
                   max = 60, 
                   value = 20, 
                   step = 1), 
      
 br(), #To add a break    
      selectInput("RI", 
                  "Renal function:", 
                  choices = list("Normal" = 1, 
                                 "Mild impairment" = 2, 
                                 "Moderate + Severe impairment" = 3, 
                                 "End Stage impairment" = 4), 
                  selected = "Normal"), 
       
      br(), #To add a break 
      selectInput("SEX", 
                  "Gender:", 
                  choices = list("Male" = 1, 
                                 "Female" = 2), 
                  selected = "Male") 
    ),    
    br(), #To add a break 
     
    h4("Select Box"), 
     
    br(), #To add a break 
    checkboxInput("O", "Opioids", FALSE), 
    verbatimTextOutput("O"), 
     
    br(), #To add a break 
    checkboxInput("AR", "Asian Race", FALSE), 
    verbatimTextOutput("AR"), 
     
    br(), #To add a break 
    checkboxInput("C", "Cirrhosis", FALSE), 
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    verbatimTextOutput("C"), 
     
    br() #To add a break 
             ), #Brackets closing "siderbarPanel" 
     
    #Plot output  
    mainPanel( 
       
      tabsetPanel(type = "tabs", 
                  tabPanel("Pibrentasvir", plotOutput("plotCONC1", height = 600, width = 800)), 
                  tabPanel("Glecaprevir", plotOutput("plotCONC3", height = 600, width = 800)), 
                  tabPanel("Pibrentasvir & Glecaprevir", plotOutput("plotCONC13", height = 600, 
width = 800)) 
                 # tabPanel("Table1", dataTableOutput("table1"))         
  ) #Brackets closing "mainPanel" 
      ) #Brackets closing "sidebarLayout" 
        ) #Brackets closing "fixedPage" 
) 
 
Attachment 14 
#Load library packages 
library(deSolve) 
library(ggplot2) 
library(plyr) 
library(compiler) 
library (PKNCA) 
library(psych) 
 
#Code for functions and variables which are not reactive (not dependent on "input$X") 
#ggplot2 theme 
theme_custom <- theme_set(theme_grey(18)) 
 
#Function containing differential equations for amount in each compartment  
DES <- function(T, A, THETA) { 
  Cl <- THETA[1] 
  V1 <- THETA[2] 
  V2 <- THETA[3] 
  Q <- THETA[4] 
  Ka <- THETA[5] 
 
  dA <- vector(length = 3) 
  dA[1] = -Ka*A[1] 
  dA[2] = Ka * A[1] - (Cl/V1 + Q/V1) * A[2] + Q/V2 * A[3] 
 Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals 
 
 
66 
 
  dA[3] =  Q/V1 * A[2] -  Q/V2 * A[3] 
  list(dA)    
} 
 
#Compile DES function 
DES.cmpf <- cmpfun(DES) 
 
#TIME sequence for concentrations to be calculated 
TIME <- seq(from = 0, to = 90, by = 0.02) 
 
#TIMElast is used in later functions for assigning dose events  
TIMElast <- max(TIME) 
 
#PIB Model 
    #Collect input from user-widgets 
    SEX <- 0 
    C <- 0 
    AR <- 0 
    AGE <- 54.72 
    MRI <- 0 
    MSRI <- 0 
    ESI <- 0 
    O <- 0 
 
    #Function for calculating median, upper and lower confidence intervals for x 
    #Where x will be concentrations for GLE and PIB 
    sumfuncx <- function(x) { 
      stat1 <-  mean(x) 
      stat2 <-  quantile(x, probs=0.025, names=F)  
      stat3 <-  quantile(x, probs=0.975, names=F) 
      result <- c("mean"=stat1, "low"=stat2, "hi"=stat3) 
      result 
    } 
 
    Cl <- 6340 
    V1 <- 1380     # (L) (Central Compartment) 
    V2 <- 2250     #(L) (perpheral compartment) 
    Q <- 1660      #(L/Day) 
    Ka <- 6.13 
    K12 <- Q/V1 
    K21 <- Q/V2 
    K10 <- Cl/V1 
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    #Simulate random  
    n <- 1000 
    par.data <- seq(from = 1, to = n, by = 1) 
    par.data <- data.frame(par.data) 
    names(par.data) <- "ID”  
 
    #Define population values 
    POPCl <- Cl 
    POPV1 <- V1  
    POPV2 <- V2 
    POPQ <- Q 
    POPKa <- Ka 
 
    #Define population parameter variability 
    ETACl <- rnorm(n, mean = 0, sd = 0.289) 
    ETAV1<- rnorm(n, mean = 0, sd = 0.78) 
    ETAV2 <- rnorm(n, mean = 0, sd = 0) 
    ETAQ <- rnorm(n, mean = 0, sd = 0) 
    ETAKa <- rnorm(n, mean = 0, sd = 0)   
 
    #Simulate individual values  
    par.data$Cl <- POPCl*exp(ETACl) 
    par.data$V1 <- POPV1*exp(ETAV1)  
    par.data$V2 <- POPV2*exp(ETAV2) 
    par.data$Q <- POPQ*exp(ETAQ) 
    par.data$Ka <- POPKa*exp(ETAKa)   
 
    #Input doses specific to dosing frequency   
    DOSE <- 120 # To change to micrograms 
    freq <- 1  #DAY 
    ndoses <- TIMElast/freq + 1  
    DOSEdata <- data.frame(var    = rep(1, times = ndoses), 
                           time   = seq(0,TIMElast,freq), 
                           value  = rep(DOSE, times = ndoses), 
                           method = rep("add", times = ndoses)) 
 
    simulate.conc <- function(par.data) {     
      #Parameter vector 
      THETAlist <- c("Cl"= par.data$Cl, 
                     "V1"= par.data$V1, 
                     "V2"= par.data$V2, 
                     "Q"= par.data$Q, 
                     "Ka"= par.data$Ka)  
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      #Set initial conditions in each compartment 
      A_0 <- c(A1 = 0, A2 = 0, A3 = 0) 
 
      #Run differential equation solver (deSolve pacKage)  
      sim.data.df.pib <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata)) 
    }  
 
    #Compile simulate.conc function for pib 
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
    sim.data.df.pib <- ddply(par.data, .(ID, Cl, V1, V2, Q, Ka), simulate.conc.cmpf) 
 
    #GLE model  
    Cl <- 1150 
    V1 <- 130      # (L) (Central Compartment) 
    V2 <- 39.6     #(L) (perpheral compartment) 
    Q <- 68        #(L/Day) 
    K12 <- Q/V1 
    K21 <- Q/V2 
    K10 <- Cl/V1 
    Ka <- 8.63    #(1/day) 
 
    #Simulate random  
    par.data <- seq(from = 1, to = n, by = 1) 
    par.data <- data.frame(par.data) 
    names(par.data) <- "ID" 
     
    #Define population values 
    POPCl <- Cl 
    POPV1 <- V1  
    POPV2 <- V2 
    POPQ <- Q 
    POPKa <- Ka 
 
    #Define population parameter variability 
    ETACl <- rnorm(n, mean = 0, sd = 0.118) 
    ETAV1<- rnorm(n, mean = 0, sd = 0) 
    ETAV2 <- rnorm(n, mean = 0, sd = 0) 
    ETAQ <- rnorm(n, mean = 0, sd = 0) 
    ETAKa <- rnorm(n, mean = 0, sd = 0) 
     
    #Simulate individual values  
    par.data$Cl <- POPCl*exp(ETACl) 
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    par.data$V1 <- POPV1*exp(ETAV1)  
    par.data$V2 <- POPV2*exp(ETAV2) 
    par.data$Q <- POPQ*exp(ETAQ) 
    par.data$Ka <- POPKa*exp(ETAKa) 
 
    #Input doses specific to dosing frequency 
    DOSE <- 300 
    freq <- 1  #DAY 
    ndoses <- TIMElast/freq + 1 
     
    DOSEdata <- data.frame(var    = rep(1, times = ndoses), 
                           time   = seq(0,TIMElast,freq), 
                           value  = rep(DOSE, times = ndoses), 
                           method = rep("add", times = ndoses)) 
 
    simulate.conc <- function(par.data) {  
      #Parameter vector 
      THETAlist <- c("Cl"= par.data$Cl, 
                     "V1"= par.data$V1, 
                     "V2"= par.data$V2, 
                     "Q"= par.data$Q, 
                     "Ka"= par.data$Ka)  
 
      #Set initial conditions in each compartment 
      A_0 <- c(A1 = 0, A2 = 0, A3 = 0) 
     sim.data.df.gle <- lsoda(A_0, TIME, DES, THETAlist,  events = list(data=DOSEdata)) 
     }  
     
    #Compile simulate.conc function for gle 
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
    sim.data.df.gle <- ddply(par.data, .(ID, Cl, V1, V2, Q, Ka), simulate.conc.cmpf) 
     
    #Process the simulated output  
    sim.data.df.pib <- as.data.frame(sim.data.df.pib) 
    sim.data.df.pib$CONC1 <- sim.data.df.pib$A2/sim.data.df.pib$V1 
    sim.data.df.pib$CONC2 <- sim.data.df.pib$A3/sim.data.df.pib$V2 
    sim.data.df.pib <- as.data.frame(sim.data.df.pib) 
     
    #Process the simulated output  
    sim.data.df.gle <- as.data.frame(sim.data.df.gle) 
    sim.data.df.gle$CONC3 <- sim.data.df.gle$A2/sim.data.df.gle$V1 
    sim.data.df.gle$CONC4 <- sim.data.df.gle$A3/sim.data.df.gle$V2 
    sim.data.df.gle <- as.data.frame(sim.data.df.gle) 
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    statsCONC1 <- ddply(sim.data.df.pib, .(TIME), function(sim.data.df.pib) 
sumfuncx(sim.data.df.pib$CONC1)) 
    names(statsCONC1)[c(2,3,4)] <- c("Pmean","Plow","Phi") 
    statsCONC3 <- ddply(sim.data.df.gle, .(TIME), function(sim.data.df.gle) 
sumfuncx(sim.data.df.gle$CONC3))  
    names(statsCONC3)[c(2,3,4)] <- c("Gmean", "Glow", "Ghi") 
     
    sim.data.df <- merge(statsCONC1,statsCONC3,by=c("TIME"),all=T) 
    sim.data.df <- as.data.frame(sim.data.df) 
 
   #AUC for GLE 
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
    testgle.auc <- sim.data.df.gle 
    Auc.gle <- ddply(testgle.auc, .(ID), summarise, pk.calc.auc(CONC3, time, interval = c(85, 
86))) 
     
    #Change the names of columns 
    names(Auc.gle) <- c("Subjects", "GLE.AUC") 
 
#AUC for PIB 
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
    testpib.auc <- sim.data.df.pib 
    Auc.pib <- ddply(testpib.auc, .(ID), summarise, pk.calc.auc(CONC1, time, interval = c(85, 
86))) 
     
    #Change the names of columns 
names(Auc.pib) <- c("Subjects", "PIB.AUC") 
     
    #Merge both tables of AUC 
    Auc.data.df <- merge(Auc.gle,Auc.pib,by=c("Subjects"),all=T) 
    Auc.data.df <- as.data.frame(Auc.data.df)  
 
#Cmax for GLE         
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
    testgle.cmax <- sim.data.df.gle 
    cmax.gle <- ddply(testgle.cmax, .(ID), summarise, pk.calc.cmax(CONC3, check = TRUE)) 
    
 #Change the names of columns 
    names(cmax.gle) <- c("Subjects", "GLE.CMAX") 
     
  #Cmax for PIB   
    simulate.conc.cmpf <- cmpfun(simulate.conc) 
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    testpib.cmax <- sim.data.df.pib 
    cmax.pib <- ddply(testpib.cmax, .(ID), summarise, pk.calc.cmax(CONC1, check = TRUE)) 
     
    #Change the names of columns 
    names(cmax.pib) <- c("Subjects", "PIB.CMAX") 
     
    #Merge both tables of Cmax 
    Cmax.data.df <- merge(cmax.gle,cmax.pib,by=c("Subjects"),all=T) 
    Cmax.data.df <- as.data.frame(Cmax.data.df)  
 
     #Merge both tables of AUC and Cmax 
    AUC.CMAX <- merge(Auc.data.df,Cmax.data.df,by=c("Subjects"),all=T) 
    AUC.CMAX <- as.data.frame(AUC.CMAX) 
 
    #Save file in excel 
    write.csv(AUC.CMAX, "AUC&CMAX.csv")  
 
  #Generate a plot of the data 
  #Also uses the inputs to build the plot (ggplot2 package) 
     plotobj <- ggplot(sim.data.df) +  
      geom_line(aes(x = TIME, y = Pmean), colour = "red", size = 1) +  
      geom_line(aes(x = TIME, y = Gmean), colour = "blue", size = 1) + 
      geom_ribbon(aes(x = TIME, ymin = Plow, ymax = Phi), fill = "red", alpha = 0.3) + 
      geom_ribbon(aes(x = TIME, ymin = Glow, ymax = Ghi), fill = "blue", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)") 
    print(plotobj) 
     
    plotPIB <- ggplot(sim.data.df) +  
      geom_line(aes(x = TIME, y = Pmean), colour = "red", size = 1) +  
      geom_ribbon(aes(x = TIME, ymin = Plow, ymax = Phi), fill = "red", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)") 
    print(plotPIB) 
     
    plotGLE <- ggplot(sim.data.df) +  
      geom_line(aes(x = TIME, y = Gmean), colour = "blue", size = 1) + 
      geom_ribbon(aes(x = TIME, ymin = Glow, ymax = Ghi), fill = "blue", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)") 
    print(plotGLE) 
     
    plotPIB <- ggplot(sim.data.df) +  
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      geom_line(aes(x = TIME, y = Pmean), colour = "red", size = 1) +  
      geom_ribbon(aes(x = TIME, ymin = Plow, ymax = Phi), fill = "red", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)", limits = c(85,87)) 
    print(plotPIB) 
     
    plotGLE_SS <- ggplot(sim.data.df) +  
      geom_line(aes(x = TIME, y = Gmean), colour = "blue", size = 1) + 
      geom_ribbon(aes(x = TIME, ymin = Glow, ymax = Ghi), fill = "blue", alpha = 0.3) + 
      scale_y_continuous("Concentration (mg/L) \n") +  
      scale_x_continuous("\nTime (day)", limits = c(85,87)) 
    print(plotGLE_SS) 
 
    #Create a matrix for calculations 
    summary_table <- matrix(nrow = 4, ncol = 4) 
    colnames(summary_table) <- c( "GLE.CMAX", "PIB.CMAX", "GLE.AUC", "PIB.AUC") 
    rownames(summary_table) <- c("Arithmetic Mean", "Geometic Mean", "Standard 
Deviation", "Coefficient of variation") 
 
    #Arithmetic mean 
    summary_table[1,1] <- mean(AUC.CMAX$GLE.CMAX) 
    summary_table[1,2] <- mean(AUC.CMAX$PIB.CMAX) 
    summary_table[1,3] <- mean(AUC.CMAX$GLE.AUC) 
    summary_table[1,4] <- mean(AUC.CMAX$PIB.AUC) 
     
    #Geometric mean 
    summary_table[2,1] <- geometric.mean(AUC.CMAX$GLE.CMAX) 
    summary_table[2,2] <- geometric.mean(AUC.CMAX$PIB.CMAX) 
    summary_table[2,3] <- geometric.mean(AUC.CMAX$GLE.AUC) 
    summary_table[2,4] <- geometric.mean(AUC.CMAX$PIB.AUC) 
     
    #Standard Deviation 
    summary_table[3,1] <- sd(AUC.CMAX$GLE.CMAX) 
    summary_table[3,2] <- sd(AUC.CMAX$PIB.CMAX) 
    summary_table[3,3] <- sd(AUC.CMAX$GLE.AUC) 
    summary_table[3,4] <- sd(AUC.CMAX$PIB.AUC) 
     
    #Coefficient of variation  
    summary_table[4,1] <- summary_table[3,1]/ summary_table[1,1] 
    summary_table[4,2] <- summary_table[3,2]/ summary_table[1,2] 
    summary_table[4,3] <- summary_table[3,3]/ summary_table[1,3] 
    summary_table[4,4] <- summary_table[3,4]/ summary_table[1,4] 
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    #Save table in excel  
    write.csv(summary_table, "Calculations.csv") 
 
Attachment 23 
 
Subjects GLE.AUC PIB.AUC GLE.CMAX PIB.CMAX 
1 0.231129777 0.016260092 0.77616308 0.031293748 
2 0.230022985 0.013360185 0.77430177 0.033052714 
3 0.25023479 0.021087669 0.806703267 0.048680278 
4 0.240895921 0.014965226 0.79213761 0.018736928 
5 0.3020232 0.021302775 0.890079407 0.02715586 
6 0.241622726 0.030972387 0.793295303 0.036165043 
7 0.313621988 0.016730246 0.906655431 0.037489188 
8 0.287553933 0.018062922 0.868390553 0.050471407 
9 0.257759024 0.028583166 0.819612045 0.036041073 
10 0.249854097 0.022147955 0.806122317 0.027619165 
11 0.274080426 0.0116456 0.847071461 0.031931566 
12 0.290311741 0.016350804 0.87261652 0.022535211 
13 0.275115392 0.023342173 0.84875034 0.028845449 
14 0.24945543 0.015151343 0.805512801 0.032970077 
15 0.269825087 0.031982742 0.84009299 0.049099457 
16 0.324344077 0.019912866 0.921398521 0.04497202 
17 0.256419453 0.023278446 0.817271971 0.034269807 
18 0.201108411 0.021091734 0.721517866 0.02763191 
19 0.235271725 0.02591229 0.78303508 0.027450524 
20 0.212431047 0.02864286 0.743197385 0.047660288 
21 0.244049401 0.015461923 0.797130606 0.021295313 
22 0.225820466 0.012577975 0.767135467 0.041770696 
23 0.303629622 0.017494551 0.892416313 0.034311907 
24 0.242690056 0.018712045 0.794987855 0.038103372 
25 0.250444413 0.041733381 0.807022707 0.048297621 
26 0.273158093 0.017778887 0.84556928 0.034645165 
27 0.256300519 0.020027619 0.817063542 0.031467938 
28 0.223876254 0.009716144 0.763765976 0.015014078 
29 0.224012028 0.023404268 0.764002416 0.024856275 
30 0.300674339 0.011327397 0.888106601 0.037238514 
31 0.213250022 0.023823678 0.744712459 0.04076454 
32 0.26108126 0.015922354 0.825357099 0.029563208 
33 0.253735723 0.018417665 0.81254221 0.041449846 
34 0.215300236 0.022124695 0.748475261 0.043916404 
35 0.27279381 0.014354554 0.84497441 0.034647559 
36 0.250562998 0.013461904 0.807203275 0.019008784 
37 0.298053071 0.019392511 0.884244766 0.030731227 
38 0.287854222 0.022841151 0.868852893 0.054032875 
39 0.277869576 0.014876782 0.853183745 0.019901229 
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40 0.246221673 0.012917835 0.800525255 0.034714105 
41 0.220647895 0.018251011 0.758093082 0.032082367 
42 0.272849084 0.020373946 0.845064729 0.064287124 
43 0.221362479 0.013635898 0.759357245 0.046649371 
44 0.221716391 0.023940147 0.759981546 0.030809762 
45 0.310421121 0.015580158 0.902148651 0.034801635 
46 0.271347262 0.021228718 0.842603374 0.051873834 
47 0.238051253 0.022744862 0.787565861 0.036887459 
48 0.24946776 0.018370698 0.805531669 0.047988421 
49 0.279118873 0.039021712 0.855178511 0.043238169 
50 0.262553316 0.01220547 0.82787646 0.022316474 
51 0.205955337 0.015942728 0.730969451 0.028087519 
52 0.245947303 0.015468803 0.800098477 0.035354274 
53 0.210487138 0.024757288 0.739573409 0.030864304 
54 0.285987014 0.007788972 0.865969283 0.023763348 
55 0.230887411 0.011739667 0.775756403 0.030330449 
56 0.284761646 0.021516498 0.864065449 0.032627366 
57 0.272707432 0.020192935 0.844833225 0.053848735 
58 0.250800564 0.025757385 0.807564706 0.042463481 
59 0.302380719 0.025077247 0.890600678 0.083006058 
60 0.238080426 0.012239564 0.787613077 0.02704338 
61 0.251866162 0.028785747 0.809214016 0.040692085 
62 0.288483183 0.024232411 0.869819529 0.02907636 
63 0.2345135 0.047087968 0.781787984 0.056794457 
64 0.291021333 0.02021368 0.873696648 0.068764123 
65 0.244160902 0.01643901 0.79730573 0.020728931 
66 0.340559104 0.018060936 0.942741369 0.032919173 
67 0.291202709 0.033600438 0.873972263 0.062026812 
68 0.277646465 0.014391748 0.852826443 0.024889763 
69 0.302145822 0.013554629 0.890258269 0.022276331 
70 0.286447252 0.025048698 0.866681996 0.03523086 
71 0.226127828 0.019461444 0.767664979 0.02786538 
72 0.218759601 0.021834388 0.754728922 0.051962123 
73 0.202581572 0.018564065 0.724418481 0.044380833 
74 0.253303998 0.013428004 0.811776103 0.036244508 
75 0.299455423 0.020211695 0.886315447 0.033125813 
76 0.226685987 0.020041421 0.76862436 0.033794731 
77 0.247044221 0.012566918 0.801801311 0.026452201 
78 0.286036409 0.016966472 0.866045836 0.025886331 
79 0.289974609 0.026648931 0.872102316 0.029758256 
80 0.217921658 0.034638725 0.753224969 0.051556058 
81 0.243043297 0.030003904 0.795546055 0.043029186 
82 0.239244394 0.015930567 0.789491327 0.055660253 
83 0.218106745 0.019385718 0.753557757 0.041624376 
84 0.248112103 0.023521307 0.803450392 0.04083192 
85 0.317786391 0.01953349 0.912444937 0.032896136 
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86 0.275346076 0.027984433 0.849123579 0.032514246 
87 0.274904051 0.027968547 0.848408088 0.04457222 
88 0.259841491 0.02233257 0.823222864 0.044214305 
89 0.205214909 0.03210984 0.729542554 0.048813844 
90 0.244471849 0.022638372 0.797793603 0.036809408 
91 0.236872349 0.019695896 0.78565197 0.058181329 
92 0.270643298 0.015459042 0.841444364 0.044928406 
93 0.239916239 0.02368553 0.790570475 0.053236094 
94 0.307142924 0.020710551 0.897480298 0.039139367 
95 0.281163209 0.014900723 0.858421233 0.034412486 
96 0.258716802 0.018259254 0.821276806 0.046197232 
97 0.229381977 0.02432527 0.773218867 0.067254848 
98 0.222722002 0.017618274 0.761748985 0.044205389 
99 0.276410952 0.019646609 0.850841975 0.055553737 
100 0.205547269 0.017106243 0.7301838 0.028314596 
 
